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ACRONYM 
1D Mono-dimensional 
2D Bi-dimensional 
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HSQC Heteronuclear single-quantum coherence 
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kDa kiloDalton 
L Liter 
LB Luria broth 
Lys Lysine 
M Molar 
MAP Microtubule-Associated Protein 
MAPT Microtubule Associated Protein Tau (Human gene) 
mg milligram 
MHz Megahertz 
min minute 
mL milliliter 
mm millimeter 
mM millimolar 
mol mole 
MTBD MT-binding domain 
MTs Microtubules 
N-terminal amino-terminal 
NFTs Neurofibrillary Tangles 
NMR Nuclear Magnetic Resonance 
NP Nanoparticle 
OLA Oleic Acid 
P/FA Protein/Fatty Acid ratio 
PD Parkinson’s Disease 
PHFs paired helical filaments 
ppm Chemical shift in parts per million 
PUFA Poly Unsatured Fatty Acid 
R2 Transverse relaxation rate 
Rh Radius of hydration 
SDS-PAGE Sodium Dodecyl Sulfate Polyacrylamide Gel 
Electrophoresis 
SFs Straight Filaments 
TCEP tris(2-carboxyethyl)phosphine hydrochloride 
ThT Thioflavin-T 
Ub Ubiquitin 
UPS Ubiquitin-Proteasome System 
α-syn α-Synuclein 
µg microgram 
μL microliter 
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Abstract 
The aggregation of the neuronal Tau protein and the formation of neurofibrillary 
tangles is one of the major hallmarks of Alzheimer’s disease (AD) and other tauopa-
thies. The processes underlying this structural transition are still unknown. Recent 
evidence indicated that, in vivo, Tau in paired helical filaments purified from AD 
brains is characterized by several post-translational modifications including 
polyubiquitination. Due to the role of ubiquitination in the clearance of misfolded 
proteins by proteasomal degradation, dysfunction of the ubiquitin-proteasome sys-
tem was proposed to be one of the key mechanisms of neurodegeneration. In this 
context, we aim to define the effect of ubiquitination on the structural propensities 
of Tau, on its aggregation pathway to fibrils, and on its clearance. 
 
In latest years, it is becoming evident that the physiological role of Tau extends 
beyond its ability to modulate microtubule dynamics. Thanks to the identification 
of numerous binding partners, including signaling molecules, cytoskeletal ele-
ments, and lipids, its involvement in diverse activities has been suggested. Anionic 
cofactors such as lipids were proposed to play a major role in shifting conforma-
tional equilibria towards either aggregation-resistant or pro-aggregating structures. 
Lipids are abundant in the cellular environment and accessible to cytosolic Tau, and 
interactions between lipid membranes and Tau have been proposed to play a role in 
the protein’s physiological function. However, their influence on the conforma-
tional dynamics of Tau remains poorly characterized. Beyond plausible interactions 
under normal conditions, lipid-promoted Tau aggregation is of great interest due to 
its role in the process of neurodegeneration. It is known that the levels of free cyto-
solic fatty acids can be increased in pathology. In this context, we aim to investigate 
the equilibrium binding of Tau4RD to anionic lipid vesicles and fatty acids. Partic-
ularly, we are interested in identifying the polypeptide regions involved in the in-
teractions and detecting conformational transitions experienced by Tau in the pres-
ence of lipid molecules. 
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Recently, nanoparticles have attracted increasing interest as aggregation modula-
tors and were found to either accelerate or inhibit fibrillogenesis, depending on their 
properties (size, charge, hydrophobicity, material), environment (pH, ionic 
strength, temperature), NP/protein molar ratios. However, despite intense investi-
gation, our understanding of how amyloidogenic proteins interact with NPs remains 
limited. Solution NMR experiments have been increasingly used to describe the 
interaction of proteins with NPs at the individual residue level. Indeed, recent ef-
forts demonstrated that several NMR observables, such as chemical shifts, signal 
intensities, amide exchange rates, and relaxation parameters, together with newly 
designed saturation transfer experiments, could be successfully employed to char-
acterize the orientation, structure and dynamics of proteins adsorbing onto NP sur-
faces.  In this context, we aim to describe the interaction pattern of the NP-Protein 
hybrid assemblies at the individual residue level by solution NMR spectroscopy. 
The collected data should serve to figure out which conformations of the model 
proteins are prevalent at the NPs surface and to describe the relationship between 
particle features and conformational preference. 
 
In summary, the activity of this thesis project concerns the investigation of confor-
mational properties of protein Tau induced by ubiquitination and by interactions 
with lipids and nanoparticles. 
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1 Introduction 
1.1  Neurodegenerative Diseases 
Neurogenerative diseases are a very common disorder among elderly peo-
ple. In recent decades, are becoming more prevalent, although the mechanism that 
leads to progressive dysfunction and death of nerve cells in different parts of the 
human brain is still unknown1. These age-dependent disorders are becoming one of 
the most serious health and socioeconomic problems as a result of increased life 
expectancy. Indeed, in recent years, the elderly population has increased2,3 and ac-
cording to recent estimates, more than 45 million people worldwide are living with 
dementia and this number will increase to more than 130 million people by 2050 
(Figure 1)4,5. 
 
Figure 1: The chart shows the number of elderly people suffering from dementia and expected 
growth in the future. Data refer to: 2016-2050(estimates)Source: Alzheimer’s Disease Interna-
tional (ADI). 
Over the past decades, research on neurodegenerative diseases has grown: accord-
ing to a PubMed research powered by the Nation Library of Medicine for the key-
word “neurodegenerative disease”, more than 65.000 citations for the past ten years 
have been found, including over 20.000 citations each on Alzheimer disease and 
about 10.000 citations for Parkinson disease. This clearly shows that the remarkable 
advances in understanding the genetic basis of neurodegenerative diseases have 
been a major driving force in all fields of research on these disorders by opening 
many new lines of investigation. It is, therefore, necessary to continue to develop 
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new ways of advancing new therapeutic strategies in order to drastically reduce the 
mortality of these disorders in the elderly population 6,7. 
Which are the hallmarks of these diseases? According to the common lines 
of investigation, apparently there is a common pathogenesis that characterizes the 
neurodegenerative disorders: Alzheimer’s disease (AD), Parkinson’s Disease (PD) 
and others, are marked by the aggregation and deposition of misfolded proteins, 
which cause destabilization of neuroplasticity followed by neuronal cell loss, re-
sulting in specific clinical impairments 8. Almost all major neurodegenerative dis-
orders are characterized by the insidious accumulation of insoluble filamentous ag-
gregates of normally soluble proteins in the Central Nervous System (CNS) 8, as 
reported in Table 1. 
 
Diseases Microscopic Lesion Location Aggregated protein 
Alzheimer’s disease 
Amyloid plaque Extracellular Amyloid-β (Aβ) 
Neurofibrillary tangle (NFTs) Intracytoplasmic (neurons) Tau 
Lewy bodies Intracytoplasmic (neurons) α-synuclein 
Amyotrophic lateral sclerosis Hyaline inclusions Intracytoplasmic (neurons) Superoxide dis-mutase-1 (SOD1) 
Cortical basal degenera-
tion/progressive supranu-
clear palsy 
Tau positive inclusion 
Intracytoplasmic (neurons, 
oligodendroglia and astro-
cytes) 
Tau 
Dementia with Lewy bodies Lewy bodies Intracytoplasmic (neurons) α-synuclein 
Huntington disease Neuronal inclusions Intranuclear (neurons) 
Huntington (contain-
ing polyglutamine re-
peat expansion) 
Multiple system atrophy Glia cytoplasmic Intracytoplasmic (oligoden-
droglia) 
α-synuclein 
Parkinson’s disease Lewy bodies Intracytoplasmic (neurons) α-synuclein 
Pick’s disease Pick bodies Intracytoplasmic (neurons) Tau 
Prion diseases Prion plaques Extracellular Protease-resistant prion protein (PrP) 
Table 1: Neurodegenerative diseases characterized by the deposition of aggregated proteins. 
(Adapted from Skovronsky et al, 2006) 8.  
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 Alzheimer disease 
Alzheimer’s disease (AD) is the most common and prevalent neurodegen-
erative disorder, being more prevalent than Lewy body dementia (LBD) and fron-
totemporal dementia (FTD), however, despite intense efforts, it has remained an 
insufficiently understood disorder. This type of dementia usually starts slowly, af-
fecting first the parts of the brain responsible for memory, thinking and language 
and, as all neurodegenerative diseases, it is characterized by a progressive and slow 
loss of cognitive functions, directly connected to severe dementia 9. Moreover is 
marked by a decline in memory and cognitive deficits such as problems with lan-
guage, visuospatial skills, impaired judgment, and decision-making 10,11. Over time, 
these symptoms worsen to the point where patients do not recognize close relatives 
and have problems with basic daily activities. In addition to memory impairment, 
sufferers affected by this disease develop other symptoms, such as changes in mood 
and personality, changes in reasoning skills. 
Among all elderly population afflicted with neurodegenerative disorders, 
more than half suffer from AD 12, and it has been estimated that the number of 
people worldwide affected by this pathology, today ~15 million, will triple by the 
year 2050 13.  More than 95% of AD cases are diagnosed late because the main risk 
factor is determined by advanced age. Other risk factors include, as examples, car-
diovascular diseases 14, inflammation 15, and traumatic brain injury. 
Alzheimer's Disease was described for the first time a century ago, in a brief 
report of 1907 by Alois Alzheimer: a deceased patient presented the pathological 
hallmarks – plagues and tangles – of the neurodegenerative disease that later came 
to be known with his name 16. In the last two decades, the mechanisms underlying 
this pathology have come to be understood, starting from the discovery of the Ab 
protein as part of the plaques and the hyperphosphorylated Tau, as the main part of 
the NFTs 9,17,18. Although only the possible or probable AD can be diagnosed clin-
ically routinely and the certain diagnosis of AD can be made only post-mortem, the 
scientific community is still fighting to better understand this devastating disease. 
Neuropathologically, AD is characterized by the extracellular deposition of 
amyloid plaques containing the aggregated amyloid precursor protein (APP) pep-
tide fragment Aβ and the intracellular neurofibrillary tangles (NFTs) composed of 
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hyper-phosphorylated Tau protein in paired helical or straight filaments (PHFs, 
SFs) 19 (Figure 2). Amyloid deposits and NFTs are associated with normal aging; 
however, these lesions are also the two main neuropathological lesions described 
in patients with AD 20. Patients with AD show an extensive loss of nerve cells in 
the brain, resulting in a dramatic reduction of the brain mass and consequent cog-
nitive decline. Moreover, as reported, these changes in the brain can also lead to 
loss of synaptic contacts and changes in neuronal morphology 21. 
 
Figure 2: The hallmarks of Alzheimer’s disease. Senile plaques of Aβ (arrow) and NFTs of phos-
phorylated Tau protein (arrowhead) detected by silver staining of a section of the brain cortex 
(Adapted from Allsop et al., 2014) 22. 
The increase in the production and aggregation of Aβ, which leads to the 
accumulation of its toxic species, could be understood with the hypothesis of the 
amyloid cascade. According to this interpretation, the aggregation of Aβ is directly 
connected to the outset of Tau pathology in AD, known as Tauopathy. Although 
the key role of Aβ is well understood in the familial form of Alzheimer’s (due to 
dominant autosomal mutations in the precursor genes of this protein) 23, it is unclear 
how Tauopathies might be dependent on Aβ aggregation. However, it is clear that 
AD is directly linked to neuronal death due to Tau oligomerization/aggregation. 
Furthermore, it is important to note that some changes in the expression or alterna-
tive splicing of the MAPT gene are associated with AD risk although there is no 
known mutation in this gene linked to AD. Despite this, it is known that Tau is 
essential for the toxic effect of Aβ 24. Some evidence indicates an interaction be-
tween the aggregation of Tau and Aβ, both in vitro and in vivo. As demonstrated in 
a mouse model of AD, the pathology of Aβ can facilitate the pathology of Tau by 
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accelerating Tau fibrillization. Therefore this event may lead to a reduction of the 
density of dendritic spines and cognitive impairment 25. 
 AD pathogenesis and the UPS 
In the last few years, some studies provided evidence that the ubiquitin-
proteasome system (UPS) plays a critical role in many neurodegenerative diseases, 
including AD 26, showing a stronger correlation with this disease 27.  
The UPS and the autophagy-lysosome system are two major pathways that degrade 
intracellular proteins (Figure 3) in non-pathological conditions. UPS is implicated 
in different cellular processes, like protein trafficking, antigen presentation, and 
protein degradation 28. 
 
Figure 3: Scheme of cellular pathways of protein degradation (Adapted from Jackson M.P. et al., 
2016)29. 
Moreover, UPS is the major cellular mechanism that regulates intracellular protein 
levels. UPS plays an important role in eliminating damaged, misfolded and mutant 
proteins 30.  
UPS substrates are directly connected with Ubiquitin, a highly conserved protein. 
It binds covalently to the damaged protein, targeting it to the proteasome, where it 
will be degraded by proteolysis 28,31. 
Dysfunction in the UPS may initiate or facilitate the aggregation of Tau, 
however, there is a direct interconnection between abnormal UPS activity and PHF 
formation. In fact, impaired proteasome function might be the consequence of AD, 
instead of the cause of Tauopathies 27. 
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 The Ubiquitination Machinery 
Ubiquitin (Ub) is an 8.5 kDa regulatory protein found in almost all tissue in 
many eukaryotic organisms, it contains a 76 residue highly conserved, in a wide 
variety of eukaryotic organisms 32. Regarding its role in protein degradation, Ub is 
usually linked to the target proteins through isopeptide bonds between the C-termi-
nal Gly residues of Ub and the e-amino groups of lysine (Lys) residues in proteins. 
These bonds could be done by single modification (monoubiquitination) or by one 
Ub at multiple site of the same target (multi-monoubiquitination). Furthermore, it 
can be done by the formation of Ub chains (polyubiquitination) (Figure 4) 33. 
 
Figure 4: Scheme of different ubiquitinated substrates (Adapted by Komander et al, 2012) 33.  
Ubiquitin is characterized by seven potential lysine residues (K6, K11, K27, K29, 
K33, K48 and K63) (Figure 5) that participate in chain linkage formation 34.  
 
Figure 5: Ubiquitin and its seven lysine residues (Adapted by Komander et al, 2009) 35. 
Thus, in the chains, the different Ub-Ub linkages form distinct conformations and 
consequently the fate of ubiquitinated substrate depends on the length and linkages 
 18 
type of the chains, but also depends on the set of downstream interacting proteins 
that “interpret” the diverse Ub signals. As examples, substrates modified with K48-
linked poly-Ub are usually targeted for degradation by the 26S proteasome 36. 
Whereas K63-linked poly-Ub play a non-degradative role and have been implicated 
in DNA damage tolerance, NF-kB activation and other pathways implicated in re-
ceptor endocytosis and sorting 37. 
The natural ubiquitination process is based , in vivo, on a complex machin-
ery, based on multi-enzymes cascade involving E1 (Ub-activating), E2 (Ub-conju-
gating), E3 (Ub-protein ligase) enzymes (Figure 6) 38. 
 
Figure 6: Scheme of the Ubiquitin System 
In an ATP-dependent first step, a ubiquitin-activating enzyme, E1, activates Ub at 
its C-terminal residue, with the release of AMP. The Ub activation by E1 enzyme 
is a crucial event that constitutes an important and unique starting point of the UPS. 
The Ub-activated is then transferred to an active site Cys residue of a ubiquitin-
carrier protein, E2. The Ub C-terminus is attached to the E2 catalytic cysteine res-
idue via thioester linkage catalyzing the transfer of the activated Ub to an interme-
diate. Finally, an E3 ligase acts as an adaptor that binds both substrate and Ub-E2, 
allowing an efficient transfer of Ub from the E2 to the substrate, by hardly under-
stood mechanisms. 
The human genome encodes for different forms of these enzymes: two E1 
enzymes, 37 E2 enzymes, and over 600 E3 ligases, and many other enzymes for 
stretching chains and de-ubiquitinases enzymes. This wide enzymatic variety indi-
cates that the ubiquitination process is extremely specific and regulates many sub-
strates proteins. 
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1.2 Tau protein 
In eukaryotic cells, the cytoskeleton is a functional network involved in a 
diverse range of cellular activities, such as mitosis, meiosis, motility, morphogene-
sis and intracellular trafficking. The core components of this network are the mi-
crotubules (MTs), intracellular structures composed of a heterodimer of alpha and 
beta tubulin proteins. MTs are highly dynamic and exhibit a non-equilibrium be-
havior termed dynamic instability, in which MTs undergo rapid stochastic transi-
tions between growth and shortening, as a result of the association and/or dissocia-
tion of tubulin dimers at its extremities 39. The stability and dynamics of the assem-
bly of MTs are promoted by proteins which are known as Microtubule-Associated 
Proteins (MAPs) 20. Among these MAPs, Tau is a major protein that participates in 
the association-dissociation of the MTs, conferring dynamics and polymerization 
to the system 40 (Figure 7). 
 
Figure 7: Cartoon showing MT decorated with adsorbed Tau (Adapted from Choi et al., 2009) 42. 
Tau is described as a highly soluble, natively unfolded and extremely heat-stable 
protein. It is predominantly expressed in the neurons (preferentially localized to the 
axons), where it plays a critical role in tubulin assembly and stabilization of micro-
tubules, thereby promoting the normal function of neurons 20. 
In the human, Tau is encoded by the MAPT gene, located on the long arm 
of chromosome 17 43. There are mainly six Tau isoforms in the brain, showing dif-
ferences in their primary structure due to the presence or absence of some specific 
exons 44 (Figure 8). 
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Figure 8 (A) Schematic representation of the human Tau gene and (B) six isoforms in the human 
brain. (Adapted from Gao et al., 2018) 45. 
 Structure and Function of Tau Protein 
The primary structure of Tau protein consists of an N-terminal acidic por-
tion followed by a proline rich region and the C-terminal tail, which is the basic 
part of the protein (Figure 9) 46,47. In other words, Tau can be described as a dipole 
with two domains of opposite charge, which can be modulated by post-translational 
modification 47. 
 
Figure 9: Schematic representation of the functional domains of the full-length Tau sequence 
(Adapted from Shammas et al., 2015) 48. 
The N-terminal part is known as “Projection Domain” (amino acids 1-243), since 
it projects from the microtubule surface, where it may interact with other cytoskel-
etal elements and plasma membrane 49 (Figure 9). In certain types of axon, the N-
Gao et al. Tau in neurodegeneration
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2018;6(10):175atm.amegroups.com
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Figure 1 Tau gene and six isoforms in the human brain. (A) Tau gene, MAPT, comprises 16 exons (E). N1 and N2 is encoded by E2 (green) 
and E3 (purple), respectiv ly. The repeat R2 is encoded by E10 (red). E1, E4, E5, E7, E9, E11, E12, and E13 constitute the basic component 
of tau protein. E0 and E14 are non-coding (white). E4a (yellow) is transcribed only in peripheral tissue. E6 and E8 are not expressed in 
human brain (pink). The tau isoform is composed of four areas: a N-terminal region, a proline-rich domain, a MBD, and a C-terminal 
projection region; (B) there ar  six main isoforms of tau expressed in he human brain, which are generated by alternative splicing E2, E3 
and E10. There are equal amount of 3R and 4R tau in normal human brain. However, in neurodegenerative diseases, this balance is often 
broken. 
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human tau protein is composed of four areas: an N-terminal 
region, a proline-rich domain, a microtubule-binding 
domain (MBD), and a C-terminal projection region (3). 
There are six main isoforms of tau expressed in the human 
brain, which are generated by alternative splicing around 
the N-terminal region [exon 2 (E2) and E3] and MBD 
(E10) (4). They differ from each other depending on the 
number of 29-aminoacid inserts, and the presence of three 
microtubule binding repeat sequences (3R) or 4R (5). The 
difference is that 4R tau has four microtubule binding 
repeat sequences due to the inclusion of E10, which is not 
included in 3R tau. In the normal human brain, there are 
equal amounts of 3R and 4R tau, but this ratio is often 
changed in neurodegenerative diseases.
Biological functions of tau 
As a microtubule-associated protein, tau is supposed to be 
essential for the regulation of microtubule structure and 
dynamics by binding to the icrotubule surface through 
the MBD and adjacent regions. Tau may regulate axonal 
transport by binding to the microtubule. Based on the 
graded distribution of the tau along the axon, the cargo 
can be detached from motor proteins, increasing axonal 
transport efficiency (6,7). With tau-knockout mice having 
been widely applied in the research, recent reports have 
revealed several novel functions of tau, such as maintenance 
of the integrity of genomic DNA (8,9), regulation of 
neuronal activity (10-13), neurogenesis (14,15), iron 
export (16) and long-term depression (LTD) (17,18). 
Understanding the additional functions of tau is not only 
essential to elucidate the tau pathogenesis, but is also 
necessary to ascertain the tau-based therapeutic strategy.
Tau in neurodegenerative diseases
Tau in Alzheimer’s disease
With the aging of global population, AD is becoming one 
of the greatest health-care challenges in the twenty-first 
century (19). Over the past decade, significant advances 
have been reported in understanding the roles of tau in 
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terminal region of Tau plays a crucial role in their stabilization and organization, 
because the projection domain determines the spacing between MT in axon and 
may increase axonal diameter 50. The C-terminal part is known as “Microtubule 
Binding Domain (MTBD)” (amino acids 244-369), characterized by four repeated 
domains (R1-R4) with which Tau protein binds and stabilizes MT. These repeats 
consist of stretches of a highly conserved 18-residue segment that are imperfectly 
repeated in the protein, separated by flanking regions 51,52. Within the R1-R2 and 
R2-R3 two hexapeptide motifs were identified, which are crucial for Tau change in 
conformation and induce microtubules. These two motifs are the most potent part 
to induce microtubule polymerization, but also have a high β-sheet-forming pro-
pensity 48, and are further characterized as drivers of the abnormal self-assembly of 
Tau 5. 
Tau is a heat resistant protein and limited affected by acid treatment without 
loss of its function, as the common MAPs 41. This property is probably due to the 
low content of secondary structure which is deduced from data collected with var-
ious biophysics techniques, like CD, FTIR, and NMR, which exclude the existence 
of stable secondary structure elements 53–55(Figure 10). Consequently, this low con-
tent of secondary structure 56, combined to its highly flexible conformation, classify 
Tau as a "natively unfolded" protein 57. 
 
Figure 10: The naturally unfolded nature of Tau protein. A. 1H-15N HSQC Spectrum of typical 
unfolded protein with poor signal dispersion and with the protons signals occupying only 1ppm. 
B.CD Spectrum, shows a dip at 200 nm corresponding to random coil. C. FTIR Spectrum, the 
peak at ~ 1645 cm-1 indicates the random coil typical structure. (Adapted from (A)Lippens el at, 
2006; (B) Gorantla et al, 2017; (C) von Bergen et al, 200158–60) 
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Consequently, it has not yet been possible to obtain a structural analysis using crys-
tallography. Therefore, nuclear magnetic resonance spectroscopy (NMR) has been 
proposed as a method that could allow a description of Tau conformations and dy-
namics with high resolution 61. Combining NMR with a wide range of experimental 
techniques, like FRET, EPR, SAXS, as well as computational studies, can be pro-
vide a consistent description of the three-dimensional structure 54,55,62. Moreover, 
measurements of gyration and hydrodynamic radii pointed to an average structure 
slightly more compact than that expected for a polypeptide in complete random coil 
conformation 54,62. Combining these analyses, in 2006 was proposed an original 
folded form for this protein in the unbound state in solution, known as “paper clip” 
fold. In this original folded form, the C-terminus folds over the MTB region, while 
the N-terminus folds back over the C-terminus, bringing both termini in close prox-
imity 55 (Figure 11). Particularly, in the MTB region, the conserved hexapeptide at 
the beginning of the Tau repeats R2 and R3 converts the protein into this particular 
conformation 63. 
 
Figure 11:“Paper-Clip” model of soluble Tau (Adapted from Guo et al., 2017 and Jeganathan et 
al., 2006) 64,65. 
Although efforts have focused on the characterization of the structure of this 
protein, its intrinsically disordered nature 53, combined with its multiple post-trans-
lational modifications 66, and the occurrence of six isoforms 67, makes it is difficult 
to define precisely its function. 
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 Conformational Rearrangements of Tau Protein 
The dynamic structure of Tau is influenced by the presence of chemical 
modifications and conformational rearrangements upon interaction with binding 
partners 63,68–70.This leads to the most prominent conformational transition of Tau, 
that is the formation of supramolecular structures in a self-assembly process, that 
eventually leads to the accumulation of insoluble deposits of Tau aggregates 71,72. 
Moreover, it also appears that this aggregation could be nucleated by the two hex-
apeptide motifs probably due to the propensity of these residues to form β struc-
ture73. Remarkably, unmodified Tau is highly soluble and has very little tendency 
to aggregate in solution, and does not show any evidence of adopting stable sec-
ondary or tertiary structure 41. It is possible that the formation of the “paper-clip” 
structure contributes to preventing protein self-assembly 55. 
By contrast, truncated forms of Tau do not acquire this conformation and are more 
prone to aggregation 74. 
Although point mutations that reinforce β-propensity and specific chemical 
modifications were reported to accelerate fibrillization of Tau in vitro, the inducers 
of Tau aggregation in neurons and the structure of the aggregation-competent in-
termediate(s) remain currently unknown 75. 
According to recent evidence, it is becoming clear that the physiological role of Tau 
goes beyond its ability to modulate microtubule dynamics 76,77. Indeed, the identi-
fication of different and numerous binding partners (such as signaling molecules, 
cytoskeletal elements and lipids) suggest its involvement in diverse activities 76. 
Anionic cofactors such as proteins, nucleic acids, and lipids were proposed to play 
a major role in shifting conformational equilibria towards either aggregation-re-
sistant or pro-aggregating structures 75. In vitro, sulfated glycosaminoglycans pro-
mote Tau aggregation through a charge compensation mechanism 78 and similar 
effects are elicited by nucleic acids 79 and acidic lipids 80. 
 
1.2.2.1 Tau Aggregation 
One of the most significant features of a living system is the ability of the 
molecular structure to self-assemble 81, indeed, the spontaneous aggregation of pro-
teins to form a large structure is one of the elements that characterize and 
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distinguish both normal and aberrant biology 48. The pathological formation of in-
soluble aggregates via self-assembly of soluble proteins into oligomeric structures 
lays at the root of a number of human diseases, including neurodegenerative disor-
ders such as AD and PD 82.  Formation of these insoluble aggregates includes dif-
ferent proteins and there may be different and multiple causes of their abnormal 
aggregation, such as post-translation modifications. In other cases, the formation of 
these insoluble aggregates is due to the unfolded nature of the soluble protein, ex-
posing their surface for unfavorable interactions. These interactions are often local-
ized around specific regions prone to forming β-structure, which leads to highly 
stable aggregates that are not easily removed by the proteasome system 82. 
Consequently, there is a general interest in preventing or retarding and identify the 
causes of the aggregation process, to understand the onset of these diseases. 
Tau is an unfolded, highly soluble protein which, as mentioned in the pre-
vious paragraph, plays a critical role in MTs assembly, stabilization and promoting 
normal function of neurons. In many neurodegenerative disorders, including AD, 
Tau can undergo several post-translational modifications that determine the loss of 
the capacity to bind MTs, impairing the organization of the cytoskeleton in the ax-
onal process. This abnormal behavior is promoted by conformational changes and 
misfolding in the normal structure of Tau 47,83, which leads to its aberrant aggrega-
tion into fibrillary structures inside the neurons of demented individuals. Experi-
mental evidence shows that Tau undergoes conformational changes in which the 
conversion of monomer to dimer is followed by the formation of toxic oligomers 
84–88. Afterwards the oligomers aggregates form the Paired Helical Filaments 
(PHFs), leading to the formation of Neurofibrillary Tangles (NFTs) 89 (Figure 12), 
the major pathological hallmarks of AD, abundant in the brains of AD patient. This 
event can influence the stability of MTs and other processes related to Tau protein 
47,90. 
In vitro, a good model to understand the pathological Tau fibrillization has 
been developed, using polyanionic cofactors 91. These molecules, such as heparin, 
accelerate Tau fibrillization producing filamentous structures that are structurally 
similar to those found in AD 92. The molecular basis of this process is still unknown 
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but is probably attributable to an electrostatic interaction that causes structural and 
conformation changes of Tau protein that induce fibrillization 92,93. 
 
Figure 12: Scheme of Tau dissociations from MITs, leading to their destabilization. It then ag-
gregates into oligomer, PHFs and, ultimately, NTFs. (Adapter from P. Thomson, 2018) 94. 
1.2.2.2 Post-translational modification of Tau 
The mechanisms responsible for the non-functional activities of Tau protein 
are still unknown. To counter the onset of these toxic oligomers (because they have 
a high affinity to unmodified Tau molecules), cells try to hide them, triggering some 
protective processes such as phosphorylation. Unfortunately, in AD these protec-
tive process fails, leading to an increase in the amount of Tau molecules released 
available for the aggregation 95. These hypotheses are still under debate because the 
formation of this toxic PHF-core is unknown and it is likely due to a combination 
of different events in neurons, such as oxidative stress or abnormal post-transla-
tional modifications and protein degradation. 
Several studies propose as main cause of this failure, the abnormal post-
translational modifications 96,97. Tau, indeed, is subjected to a wide range of post-
translational modification that are identified in Tauopathies, like hyperphosphory-
lation, truncation glycosylation, glycation, nitration, and ubiquitination (Figure 13). 
Therefore, many different Tau binding partners can be regulatory components of 
post-translational modifications, such as protein kinase and phosphatase. Moreover, 
Tau is also a substrate for the ubiquitin–proteasome system (UPS) and for chaper-
one-mediated autophagy 98. 
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Figure 13: Illustration of the main post-translational modifications identified on Tau. The colored 
bars show the approximate sites of each modification on the largest human 2N4R Tau (Adapted 
from Guo et al, 2017) 5. 
Ubiquitination of Tau 
 
Ubiquitination is an enzymatic process that involves the binding of a ubiq-
uitin molecule to a target protein. This process is sometimes described as the mo-
lecular “kiss of death” for a protein, as the substrate usually becomes inactivated 
and is tagged for degradation by the proteasome 99. Ubiquitin-Proteasome-System 
(UPS) plays a crucial role in the regulation of intracellular proteins, removing mu-
tant, damaged and misfolded protein. Recent evidence has shown that dysfunctions 
in the UPS are directly connected to Tau degradation/aggregation and neurodegen-
eration in AD 26,30.   
The first clue for the pathological link between UPS and Tau was first identified in 
the frequent co-localization of ubiquitin (Ub) in PHFs and NFTs. Ubiquitinated Tau 
occurs in both mono-Ub and poly-Ub forms 100. Recent mass spectroscopy analysis 
on PHFs 60 observed also polyUb chains with Lys6-, Lys11-, Lys63-linkage 101–103, 
although the significance and fate of the Ub-Tau complex, particularly in relation 
to proteasomal degradation or autophagic clearance, remain unclear 27. This analy-
sis has identified that ubiquitination marks Tau at specific Lys (K) residues: K254, 
K311 and K353, all located on MBD 101. 
Among these, the canonical degradation signal formed by Lys48-linked 
polyubiquitin chains was identified, suggesting that the ubiquitination of Tau could 
be involved in early molecular events at the onset of the Alzheimer’s diseases (Fig-
ure 14). Notably, K311 belongs to one of the Tau hexapeptide motifs (VQIVYK), 
R3, proposed to be core nucleation sites for the formation of amyloid fibrils. 
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Figure 14: Cartoon of the ubiquitination site (red *) of Tau, located on MBD. 
A further clue between Ub-dependent protein degradation and Tau turnover 
comes from the identification of the Tau-E3 ligase. This ligase is the carboxyl ter-
minus of the Hsc70–interacting protein (CHIP)–Hsc70 complex, with UbcH5B as 
the E2 enzyme 104,105. CHIP was found to be able to ubiquitylate unfolded proteins 
106 before removal by 26S proteasome. This evidence supports the notion that UPS 
could be a major system responsible for the clearance of soluble Tau.  
To gain a molecular understanding of the influence of Ub on the aggregation 
propensity of Tau, it is crucial to have access to diverse ubiquitinated Tau products. 
Enzyme-based reaction protocols have been developed to produce ubiquitinated 
proteins suitable for biophysical characterization 107. Enzymatic strategies exploit 
the coordinated action of the cascade of enzymes (E1, E2 and E3) that are respon-
sible for protein ubiquitination in vivo. This approach can potentially yield great 
amounts of ubiquitinated samples, conjugated by native isopeptide bonds. Although 
the main limitation is that specific E2 and E3 enzymes need to be known. Synthetic 
and semi-synthetic chemical approaches have proven a powerful alternative to en-
zymatic strategies, while presenting limitations and drawbacks on their own 108,109. 
Despite the availability of several ubiquitin ligation methods, in vitro ubiquitination 
of Tau has not been reported so far. 
 Tau/lipids in health and disease 
Membrane lipids may be closely associated with protein aggregates for-
mation and amyloidogenesis in vitro and in vivo 110.  
The brain contains a high concentration and variety of lipids, especially fatty 
acids (FAs), second only to adipose tissue, where they play a critical role in neu-
ronal membrane fluidity and permeability, serve as energy reservoirs and function 
as second messengers signaling 111. Among all lipids, polyunsaturated fatty acids 
(PUFAs) affect the aggregation of some misfolded proteins that have been 
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implicated in neurodegenerative disorder 110,112,113. All the long-chain FAs were 
found to enhance protein aggregation to some extent. Especially unsaturated FAs 
demonstrated greater stimulation of filamentous aggregates formation 113. 
The first reports on the implication of fatty acids (FAs) on protein aggrega-
tion, described that FAs stimulated the assembly of both Aβ peptides and Tau fila-
ments in vitro 80,110. Especially, Tau-membrane interaction is the focus of numerous 
studies 114–116. Indeed, it has been suggested that Tau in AD brains may exhibit 
abnormal interactions with the neuronal cell membrane. This interactions could 
play a role in the protein’s physiological function 116,117, however the influence 
membranes on the conformational dynamics of Tau remains poorly characterized.  
Beyond plausible interactions under normal conditions, lipid-promoted Tau 
aggregation is of great interest due to its role in the process of neurodegeneration. 
Indeed, lipids are abundant in the cellular environment and therefore easily acces-
sible to cytosolic Tau. Above all, under the pathological condition in which an in-
crease in the amount of the levels of free cytosolic FAs were observed. Indeed, it 
has been reported that elevated concentrations of saturated fatty acids are able to 
cross the blood brain barrier, constituting a significant risk factor for AD 119.  
Brain neurons are particularly rich in polyunsaturated fatty acids, such as 
arachidonic (ARA) and docosahexaenoic (DHA) acids, which are liberated into the 
cytosol by the action of phospholipases 120. Tau could participate in the formation 
of co-aggregates with lipids, in analogy with the formation of such assemblies by 
a-synuclein, another disordered amyloidogenic polypeptide implicated in neuro-
degeneration 121,122. This hypothesis is supported by the observation of Tau fila-
ments associated with lipid membranes123 and by the discovery of fatty acids in 
NFTs 124. 
The importance of lipid-protein co-assembly in the onset and progress of 
amyloid diseases has been pointed out recently 114. The association of intrinsically 
disordered polypeptides with free lipids, micelles, and vesicles is predicted to dra-
matically affect the structures and physico-chemical properties of these biomole-
cules and to modulate their interactions with other molecular partners and cells. 
Thorough investigations of lipid-protein co-assembly are necessary to 
deepen our understanding of both the healthy and aberrant action of amyloid 
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proteins. Results obtained from these investigations could prove the basis for the 
development of therapeutic strategies against devastating neurodegenerative dis-
eases. 
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1.3 Nanoparticles 
In recent years, there has been a drastic increase in research, technological 
development in the field of nanotechnology 125. One of the fundamental compo-
nents of nanotechnology are nanoparticles (NPs), which are widely used in molec-
ular diagnostics and biotechnology, with many applications in in-vivo imaging, 
drug delivery systems, biosensors and many others 126–128. 
Nanoparticles are a wide class of materials that includes particulate substrates with 
a dimension less than 100 nm at least 129,130. NPs exhibit unique properties at na-
noscale such as physical, chemical and biological, compared to their respective par-
ticles at larger scales. Although NPs may differ largely in terms of dimension, 
shape, size and their material 131, they are produced with a general architecture as 
follows 132 (Figure 15): 
- A surface layer which can be functionalized with a variety of small mole-
cules, metal ions, surfactants, and polymers, depending on the desired physico-
chemical and bioactivity of the designed particles. 
- A shell layer, which is chemically different material from the core 
- The core, which is essentially the central portion of the NPs and usually 
refers to the NPs itself. Its composition is highly varied, including metals, ceramic, 
organic polymers, lipids, etc. 
 
Figure 15: Nanoparticles Structure Scheme 
The rapid development of novel nanoparticulate materials for application in 
many areas of bioscience necessitates an improved characterization of the nano-bio 
interface 126 and, in particular,  understand how NPs interact with biological systems 
Surface Layer
Core
Shell Layer
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represents a key point for the identification of the biocompatibility or bio-adverse 
interaction 133. 
The complexity, the heterogeneity and the presence of different biomole-
cules make the biological environment a unique environment to study the behavior 
of the NPs immersed in it. In this medium, in fact, NPs can interact with different 
biomolecules, such as nucleic acids, lipids, proteins 134, in particular the latter are 
most relevant because they profoundly influence NPs biodistribution and bioreac-
tivity. According to evidences, proteins may display preferential orientations with 
respect to the NP surface, mediated by specific noncovalent chemical interactions. 
 Nobel Metal Nanoparticles: Gold NP 
For centuries noble metal nanoparticles, such as gold and silver, have been 
used in several fields. In the last decades, these NPs have attracted intense scientific 
and technical interest due to their unusual optical, electronic, and thermal proper-
ties. Mostly, also for the facile synthesis and surface bioconjugation and feasibility 
in clinical diagnostics and therapeutics. 
Gold-NPs (AuNPs), in particular, represent an attractive delivery vector in 
biomedicine due to their low toxicity and unique electronic and chemical properties 
135, and are among the most abundant in scientific literature. Typically, the size of 
this AuNPs is in the range from 5 nm to 400 nm (Figure 16). Their synthesis process 
is very simple and generally is done according to the classic reduction method with 
an appropriate modification 136. Briefly, a sodium citrate solution is added to boiling 
HAuCl4 solution and the reaction solution is allowed to mix under reflux. 
 
Figure 16: TEM imaged of gold nanoparticles from 5 nm (left) to 400 nm (right) 
AuNPs are characterized by unique properties, such as size and shape that 
depend on optical and electronic features. Another feature is a high area to volume 
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ratio and the surface layer, which can be functionalized with different chemical 
groups such as thiols, phosphines, and amines, which exhibit affinity for gold shells. 
Thanks to the advantage of these functional groups, it is possible to confer greater 
functionality by anchoring ligands of various natures such as proteins, oligonucle-
otides, antibodies, etc. 
The gold nano-conjugates formed have enabled a varied range of investigation, 
such as programmed assembly and crystallization of materials, arrangements of 
NPs into dimers and trimers onto DNA templates, bioelectronics, and new detection 
methods 137. This spontaneous formation of proteins-AuNPs conjugate is well 
known 138,139. 
Indeed, introducing NPs into the biological environments, immediately interface 
with the molecules immersed in it: nucleic acids, lipids, and proteins, which form a 
dynamic biomolecular corona around them 134. 
Thus, as the first priority, it is necessary to understand the chemical nature of the 
conjugate's interaction, which in turn requires the knowledge of the structure of 
proteins on AuNPs surface 135. 
 Protein-NPs interaction 
Among all of the potential applications of NPs, the most studied is the con-
jugation with proteins. These conjugations not only stabilize the system but also 
introduces biocompatible functionalities to the NPs, for further biological interac-
tions or coupling 130,134. The formation of this interaction is due to the varied com-
position, extensive properties, sizes, and shapes of NPs, and secondly to their low 
toxicity and unique optical, chemical, and physical properties. Moreover, NPs also 
offer the benefit of carrying functional groups (amino and carboxylic groups), 
which can be used for surface modification 128. Furthermore, nanoparticles possess 
higher stability during storage, in vivo stability after administration, as well as being 
easily adjustable during preparation 128. Because of all these features, it is challeng-
ing to generalize the behavior of the biomolecule‐NP association to subtle changes 
to surface chemistry. Indeed, this can lead to large changes in binding behavior, 
altering both the soft and hard corona composition and dynamics. 
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Most of these conjugations are spontaneous without causing any protein ag-
gregation. On the contrary, when aggregation does occur, NPs can be used as a 
good platform to modulate the orientation, structure, and function of the protein 134. 
 
1.3.2.1 Nanoparticle role in protein aggregation 
The interaction of NPs with proteins can affect both protein structure and 
functions 140. In particular, in the presence of amyloid protein, NPs have the ability 
to modulate their aggregation 135,141,142. Such an effect could be probably attributed 
to the enormous surface area of NPs that could influence protein structure and func-
tion. Recent evidence has shown that NPs can interfere with the aggregation process 
of amyloid proteins, going to up- or downregulate this mechanism 134,141. Indeed, 
on one hand, the NPs may act as catalysts to facilitate the assembly of proteins into 
stable fibril aggregates by increasing the local concentration of those proteins 134,140. 
On the other hand, NPs may act as an inhibitor of fibril propagation, determining a 
monomer depletion and/or trapping of sub- and near-critical nuclei 143. Conse-
quently, it is necessary to increase our knowledge of NP-protein interactions,  and 
of established mechanisms of protein amyloid aggregation, in order to explore the 
possible scenarios in which NPs interfere with protein aggregation pathways 144. 
 
1.3.2.2 Methods used to study Protein-Nanoparticle interactions 
The interaction between protein and NPs has been widely studied with a 
range of different techniques such as mass spectrometry-based proteomics, surface 
plasmon resonance and gel filtration chromatography, especially in the spectros-
copy field this interaction is deepen investigated 145–147. 
Circular dichroism (CD) is used to obtain information of the interaction 
force and to monitor the changes in protein secondary structure after NPs addition 
148. Otherwise, Dynamic Light Scattering (DLS) is used to detect changes in hydro-
dynamic radii and electrokinetic surface potential of the NPs after the adsorption of 
biomolecules 149. Moreover, with Isothermal Titration Calorimetry (ITC) it is pos-
sible determine the energy of the interactions 150. Among all these spectroscopy 
techniques, solution NMR spectroscopy has proven to be an outstanding tool to 
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describe the coordination and exchange mechanisms of organic molecules at the 
NPs surface, as well as ligand shell composition 145,151. Solution NMR spectroscopy 
is an established technique for the high-resolution characterization of biomolecules 
and recent studies are promoting new approaches to provide new information to 
understand these interactions. 
1.4 Biomolecular NMR spectroscopy 
Nuclear Magnetic Resonance (NMR) spectroscopy has proven to be a val-
uable tool in the studies of IDPs. Above all, in addition to its normal application for 
determination of 3D structure at atomic resolution of folded protein in solution, is 
unparalleled in its capability to provide detailed structural and dynamical infor-
mation on unfolded proteins 152. The proton chemical shift dispersion and line width 
give first information about the state of proteins: poor protein chemical shift chem-
ical shift dispersion is indicative of disorder 152. 
This powerful technique is one of the few comprehensive sources for information 
on unstructured/partly structured proteins and, moreover, on the protein folding 
process 153,154. 
 Protein NMR spectra 
Nuclear Magnetic Resonance is a phenomenon that occurs when the nuclei 
of particular atoms are immersed in a static magnetic field and exposed to a second 
oscillating magnetic field. In a general NMR experiment the sample nuclei are ori-
ented by a strong magnetic field (in the order units of Tesla), absorb radiation at 
characteristic radiofrequency (about 50-1000 MHz) and undergo an energetic tran-
sition between two states. Then, the magnetization decay (FID, free induction de-
cay), necessary to reach the equilibrium state, is converted by Fourier-Transfor-
mation in the frequency-domain from the acquired time-domain data. Nuclei of the 
same element in different environments give rise to distinct spectral lines because 
they absorb radiation at characteristic frequencies. The different parameters that can 
be measured from the resulting spectra could give information about molecular 
structure, conformation and dynamics. 
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Different elements have nuclei suitable for NMR spectroscopy: hydrogen (1H, the 
proton) is the most sensitive nucleus detected by NMR and it is by far the most 
important nucleus for the study of biological molecules. Other nuclei especially 
relevant are nitrogen (15N isotope) and carbon (13C isotope) which unfortunately 
represent only 0.4% and 1%, respectively, of the naturally occurring isotopes. 
The main problem that occurs in NMR study of proteins is that these big 
molecules contain thousands of protons that determine the overlapping of signals 
in the 1H spectrum. In order to overcome this problem, the common approach is 
labeling the molecule with isotope such as 15N and 13C which, together with multi-
dimensional heteronuclear NMR, are crucial to extend NMR analysis to larger mol-
ecules. This can be done only thanks to the development of the molecular biology 
technique and to the ability to set overexpression systems, which allow obtaining a 
large quantity of isotopically labeled molecules in the order of milligrams (optimal 
quantity for NMR experiments). 
The most basic parameters to consider during NMR experiments with IDPs 
includes buffer composition, pH, ionic strength and temperature 155. Buffers are 
often used at low concentration (10-50 mM), and non-protonated buffers, such as 
phosphate buffers, are usually used to prevent overlap in NMR signals from the 
samples. In terms of pH, a physiological value, close to pH 7, is often chosen to 
obtain an optimal quality of the NMR data. The ionic strength, with IDPs, is an 
important parameter to be checked to acquire biologically relevant data. The ionic 
force, in fact, directly influences the formation of electrostatic interactions, going 
partially to shield the molecule's charges 156; it may impact the association and dis-
sociation rates of complexes 157; and finally it may affect the data quality, because 
a high ionic strength (> 200 mM) needs setting longer pulses, thus increasing sam-
ple heating and reducing the signal to noise (especially using cryogenic probes). 
NMR measurements of IDPs require several other components to be added 
to the sample: an internal chemical shift reference, such as	4,4-dimethyl-4-silapen-tane-1-sulfonic	acid	(DSS),	for	standardization	of	the	resonance	frequency	to	chemi-cal	shift	values	in	ppm; 5%–10%	(v/v)	D2O,	to	lock	the	instrument	frequency, and NaN3	can	be	added	to	prevent	microbial	growth.	Lastly,	several	IDPs	have	free	cyste-ines	and	need	reducing	agents	for	the	measurements,	such	as	β-mercaptoethanol	or	
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dithiothreitol	 (DTT)	 or	 tris(2-carboxyethyl)phosphine	 hydrochloride	 (TCEP)	 155,158.	NMR	data	acquisitions	of	IDPs	are	often	conducted	at	low	temperature	(5-10°C)	to	slow	down	amide	exchange.	
 Protein Fingerprinting: 1H-15N-HSQC 
One of the applications of NMR is the investigation of the interaction sites 
in a protein-ligand complex, performed by monitoring the perturbations of chemical 
shifts (chemical shift perturbation, CSP), linewidths and/or intensity changes of HN 
and 15N resonances upon binding or interaction with partners. Within the arsenal of 
NMR experiments, this analysis is often done with 1H-15N-HSQC, an invaluable 
tool for protein analysis. 
The Heteronuclear Single Quantum Coherence (1H-15N-HSQC) experi-
ments are the simplest and most useful two-dimensional (2D) pulse sequence, to 
study chemical shift and/or intensity variations of protein signals in a residue-spe-
cific manner. This kind of experiment is commonly used in the field of protein 
NMR, for correlating the 15N nucleus with its attached proton in the backbone am-
ide groups of proteins, by exploiting the coupling between the two nuclei (JHN= 
92 Hz). 
The resulting 1H-15N-HSQC spectrum represents the “fingerprint” of a pro-
tein, in which the number and the position of each signal are specific for each pro-
tein sample. Each signal is defined by parameters that provide different information 
on the changes in chemical environment: position (the resonance frequency or 
chemical shift), intensity (the concentration of each population), width and pertur-
bation. Chemical shift (the resonance frequency position) and intensity changes are 
sensitive indicators of interactions among proteins in simple buffers and in presence 
of perturbing agents. Indeed, protein NMR signals are expected to be perturbed by 
the presence of ligands dispersed in the solutions or nanoparticles (NPs), and also 
by the nature of the interactions (protein-ligand/NP) and the physico-chemical 
properties of the perturbing agents. The chemical shift of a given nucleus, in pres-
ence of an interaction, will report on its local chemical environment, while, the sig-
nal intensity will depend on the number of nuclei resonating at a given frequency. 
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The chemical shift value, reported as parts per millions (or ppm), is a fun-
damental parameter in protein NMR. It defines the "NMR sensitivity", as it gives 
separately detectable signals for the hundreds of nuclei that can, therefore, be dis-
tinguished and assigned. The high NMR sensitivity of the chemical shift to structure 
and environment is very much evident in proteins. Chemical shift dispersion arises 
because different residues experience different microenvironments. 
 Translational diffusion 
NMR spectroscopy is an optimal technique for studying protein-ligand in-
teractions because a single analysis can give a big amount of structural information 
without destroying the sample. Many solution-state NMR techniques have been de-
veloped to study protein-ligand interactions, based, often, rely on monitoring 
changes in protein chemical shift and require labeled proteins 159. 
An alternative approach for studying protein-ligand interaction are diffusion 
NMR experiment. This kind of experiment can be used to resolve different com-
pounds spectroscopically in a mixture based on their differing diffusion coeffi-
cients, depending on the size and shape of the molecules. Moreover, it may be used 
to determine the size of molecules and aggregates, determining the degree of 
polymerization, size of a solvation shell or other microscopic structure. Typically, 
diffusion experiments refer to translational diffusion, which is the random transla-
tional (or Brownian) motion of molecules, driven by internal thermal energy. It is 
the basic mechanism by which molecules are distributed in space and it plays a 
central role in any chemical reaction since the reacting species have to collide be-
fore the reaction can occur. These NMR measurement represents an optimal ap-
proach to perform a qualitative and quantitative analysis of the samples 159. It is an 
extremely useful method because it is very rapid, simple and selective, allowing to 
analyze simultaneously many different binding partners. 
In the field of IDPs, diffusion measurement can be used to obtain infor-
mation about the overall size of a complex in terms of hydrodynamic radii (Rh). 
Especially is useful in order to value the compactness among the free and bound 
states. Moreover, it can also be used to determine the KD by measuring diffusion 
constants at different ligand concentrations 160.	
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In order to measure diffusion on free and bound states of the IDP, isotope labeling 
is combined with the use of filtered pulse schemes to avoid signals from the unla-
beled binding partner 161. The diffusion coefficient is inversely proportional to the 
hydrodynamic radii (Rh). Thus, binding partners (which assume the diffusion prop-
erties of the protein) can easily be distinguished from free-molecules by significant 
differences in diffusion coefficients 159, allowing to resolve otherwise intractable 
spectra of a mixture. 
The diffusion NMR technique is achieved by combining radio-frequency pulses as 
used in routine NMR spectroscopy with magnetic field gradients that encode spatial 
information. 
More simply, in this kind of experiment, the magnetization is parallel to the external 
field. Then the magnetization is excited with a 90° radiofrequency pulse then dis-
persed using a magnetic field gradient pulse. After a period of Δ/2, a 180° radiof-
requency pulse inverts the dispersed magnetization such that after a period of Δ the 
magnetization is negative compared to the initial one (Figure 17). 
 
Figure 17: The main NMR sequences used to measure translational diffusion.  
At this point, a second gradient pulse is applied to refocus the signal. 
Diffusion causes some of the nuclei to move away from where their signals can be 
refocused, thereby reducing the intensity of the resulting signal. The pulse sequence 
is repeated, many times incrementing the gradient strength and keeping the delays 
constant.  
The typical results of diffusion experiment are a plot of intensity against 
gradient strength (Figure 18). 
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Figure 18: Gaussian fit to diffusion peak intensity using a non-linear fit. 
Signal amplitudes are then extracted, and the translational diffusion coefficients (D) 
obtained by fitting the signal decay to the Stejskal–Tanner equation (Eq. 1): 
𝐼 = 𝐼!	𝑒"#!$!%!&∆""#()  (1) 
Where g	is the gradient strength, γ	is the gyromagnetic ratio (4257s-1 G-1 for proton), 
δ and Δ	are	delays. Then, the D can be extracted using a non-linear curve fit to the 
resulting Gaussian decay (Figure 18). 
Under conditions of fast exchange, the coefficient D measured on a protein 
sample in the presence of interacting partners, such as ligands, lipids, and NPs, is 
expected to decrease, due to the increased size of the complex/aggregate, according 
to the Stokes-Einstein law: 𝐷 = 𝑘𝑇6πη𝑅ℎ 
 Dark-state exchange saturation transfer (DEST) 
The ability to characterize the dynamics and the structure of increasingly 
large biological macromolecules in solution using recent NMR methods has ex-
panded the understanding of biomolecular function at the atomic level 162. Although 
several methods exist for high-resolution structural and dynamic characterization 
of proteins, none of traditional solution NMR techniques is able to observe, with 
atomic resolution, the dynamic equilibrium between an observable form and very-
high-molecular-weight complexes. Some of these high-molecular complexes can 
be formed upon interaction with membranes, multiple copies of the same molecule, 
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or with nanoparticles. More specifically, the interaction of protein-NPs (P-NPs) can 
form particular large supramolecular adducts, whose understanding may provide 
useful information about what influences NP-clearance, their biodistribution, and 
their toxicity.  
These adducts are characterized by slow molecular tumbling which causes 
very fast transverse spin relaxation (R2). Traditional NMR experiments based on 
R2 measurement are typically used to characterize the molecular dynamics. Espe-
cially 15N-R2 is used to measure the 15N relaxation, directly probing the 15N-1H bond 
vectors of amide groups, because they are directly related to backbone internal mo-
tion and the over-all molecular tumbling. Relaxation is a phenomenon that happens, 
every time when the equilibrium of the system is regained and arises from the mod-
ulation of the effective local magnetic fields. Therefore, this phenomenon is sus-
ceptible to time-dependent modulation by protein motion, thus providing a direct 
relationship between internal dynamics and relaxation 163.  
Unfortunately, when a small molecule binds to a high (≥1 MDa) molecular 
weight entity, this reduced the rate of molecular dynamics. Consequently, this leads 
to a marked increase in the R2, thus precluding the observation by standard solution 
NMR techniques. 
In recent years a novel solution NMR method has been developed, known as Dark-
State Exchange Saturation Transfer (DEST) that allows obtaining interaction ki-
netics and residue-by-residue dynamic information in the "NMR-invisible" (dark) 
bound state 162,164. However, with DEST is possible to observe the large difference 
in R2 between the free and bound state. 
DEST experiments are essentially based on the transfer of the 15N-magnetization of 
the observable species by chemical exchange to the corresponding invisible state, 
partly perturbed, and therefore saturated. Subsequently, saturation is transferred 
back upon dissociation from the high-molecular-weight species 145,164. In other 
words, it is based on a two-dimensional transfer-of-saturation NMR experiment in 
which is possible to exploit the exchange process between NMR invisible (“dark 
state”) and easily observed free unbounded state 162.  
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DEST allows an efficient partial saturation of 15N longitudinal magnetiza-
tion of the bound form by a weak radio-frequency field, even at large offsets where 
the free-molecules magnetization is completely unaffected 162.  
DEST, unlike others NMR saturation methods, is a quantitative technique because 
it uses heteronuclear (i.e.15N) saturation pulses 162,165. Above all, this technique 
avoids possible problems with rapid dipolar-coupled magnetization transfers, that 
are observed for 1H saturation examples, even in the case of sparse protonation 
162,166. 
HSQC experiment in combination with DEST allows to obtain a single-res-
idue resolution dynamic information on the NP-bound protein (the NMR-invisible 
state) in the form of 15 N- R2 values 162. 
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2 Aim of the thesis project and brief summary of the research 
activities 
The main focus of this Ph.D. thesis is the investigation of the molecular properties 
of protein Tau and their perturbations induced by post-translational modification 
and by the interaction with fatty acids and nanoparticles. 
 
As part of this Ph.D. thesis, we investigate at a molecular level, the key role of 
ubiquitination of Tau and its effect on the propensity of Tau on its aggregation 
pathway to fibrils. We focused on the four-repeat domain of the MBD of Tau 
(Tau4RD), for which an accelerated aggregation into bona fide fibrillar structures 
was reported 167.  Taking the advantage ubiquitination process based in vivo we aim 
to ubiquitinate Tau by an in vitro reaction. The reaction was conducted exploiting 
the cascade of enzymes E1, E2N (human analogue of UbcH5B), and CHIP. The 
ubiquitinated products were characterized by mass spectroscopy and SDS-PAGE.  
Then the impact of this chemical modification on the propensity of Tau to aggregate 
into fibrils were monitored by aggregation assays based on changes in Thioflavin-
T fluorescence during incubation with the aggregation inducer heparin. Finally, the 
morphology of the aggregates was inspected using AFM. 
 
As a second goal of our research, we aimed to investigate the binding of Tau4RD 
to polyunsaturated fatty acids. Particularly, we are interested in identifying the pol-
ypeptide regions involved in the interactions and detecting conformational transi-
tions experienced by Tau in the presence of lipid molecules. Interaction between 
these molecules was investigated by aggregation assays based on Thioflavin-T flu-
orescence. The acquisition of secondary structure elements was monitored by the 
use of circular dichroism measurements. The aggregated products were character-
ized by gradient SDS-PAGE to better identify the formation of high molecular 
weight species. NMR spectroscopy was used for the observation of lipid-induced 
perturbations at the single-residue level. Finally, AFM was used to characterize the 
morphology of the coaggregates. 
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As a third goal, in this Ph.D. project, we aimed to understand how amyloidogenic 
proteins, Tau (Tau4RD) and α-synuclein, interact with nanoparticles (NPs). Indeed, 
NP show promise as new-concept aggregation modulators, capable to redirect ab-
errant protein self-assembly. For our experiments we used ultrasmall gold-NPs 
functionalized with lipoic acid (Figure 19). 
 
Figure 19: Schematic representation of Lipoic Gold Nanoparticles 
Lipoic capped gold-NPs are uniform spherical gold-NPs with a high monodisperse 
size distribution. These nanoparticles bear a self-assembled monolayer of thioctic 
acid carrying a carboxylate end group, constituting a platform for many applications 
such as target-specific drug delivery, sensors, imaging probes for darkfield micros-
copy, cancer photothermal therapy and optoelectronic. 
Solution NMR experiments have been increasingly used to describe protein-nano-
particle interactions at the individual residue level. Here, we wish to gather infor-
mation about the conformations of the model proteins at NPs surfaces and to de-
scribe the relationship between particles features and conformational preference. 
Our studies challenge the current limits of the technique to obtain direct measure-
ments on particle-protein or protein-protein assemblies. 
  
Lipoic Gold NPs Citrate Gold NPs
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3 Materials and Methods 
3.1 Reagents 
All reagent used in this PhD thesis were purchased from Sigma Aldrich ex-
cept where indicated. 
3.2 Material for protein expression 
 Plasmids and Escherichia coli strains for recombinant protein ex-
pression 
Tau4RD 
E. coli codon-optimized human Tau cDNA gene was purchased from Eurofins Ge-
nomics. Tau4RD (spanning residues Q244-E372 plus initial Met) (Figure 20) was 
cloned into a pET22b(+) vector via NdeI-BamHI sites with a stop codon to avoid 
insertion of a C-terminal histidine-tag. 
 
Figure 20: Schematic representation of the primary sequence of Tau protein full length, and the 
amino acid sequence of the Tau4RD construct used in all of these studies. (Adapted by Barrè et 
al, 2013) 168. 
The plasmid pET22b(+) (purchased by Novagen) is a 5493bp expression vector 
with T7 promoter and terminator flanking MCS that accepts insert of interest. It is 
characterized by a pelB leader sequence for subcellular targeting and tag csd, amp 
resistance and many restrictions enzyme cloning. The Figure 21 shows the vector 
map of pET22 and the elements characterizing this vector. 
FL Tau
Tau4RD
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Figure 21: pET-22b(+) vector map. 
BL21(DE3) host strain was transformed with the plasmid containing the 
Tau4RD sequence. This host strain is suitable for transformation and high-level 
protein expression using a T7 RNA polymerase-IPTG induction system. 
In parallel, N-terminal histidine6-tag Tau4RD gene was cloned into a pET15b vec-
tor via NdeI-BamHI sites and which was then inserted in BL21(DE). 
Ubiquitin Machinery  
The ubiquitin protein and all the enzymes necessary for the in vitro protein ubiqui-
tination were expressed and purified using: 
- N-terminal histidine6-tagged ubiquitin gene cloned into a pET15 vector and 
expressed in E. coli Rosetta (DE3) cells; 
- N-terminal histidine6-tagged Human E1 (UBE1) gene cloned into a 
pET21(+) and expressed in E. coli Rosetta (DE3) cells; 
- N-terminal GST- tag Ubc13 (human E2N, UniProtKBP61088) and E3 ubiq-
uitin-protein ligase CHIP (UniProtKB Q9UNE7) gene cloned into a 
pGEX4T1 vector and expressed in E. coli Rosetta (DE3) cells; 
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 Heat shock transformation 
The following protocol has been used to transform BL21/Rosetta competent 
cells through heat shock:  
• 50 μl of competent cells stored at -80 °C were placed in ice for thawing 
• 30-50 ng of DNA were added, and the culture was incubated in ice                   
for 30 minutes 
• the heat shock was carried out by placing the culture in a water bath at            
42 °C for 45 seconds without shaking 
• the culture was immediately placed in ice for 2 minutes 
• 500 μl of LB medium without antibiotic was added directly to the cells and 
then the culture was incubated at 37 °C for 1 hour with                                            
shaking (200-250 rpm) 
§ the cells were plated on selective LB agar and incubated overnight at 37 °C 
3.3 Protein sample preparation 
 Glycerol stock 
After transformation, bacterial colonies with plasmid coding for protein of 
interest were grown in 5 ml LB medium with antibiotic at 37 °C for 6 hours. A cell 
solution with a final concentration of 30% glycerol was prepared, vortexed and 
cooled in liquid nitrogen. Glycerol stocks were stored at -80 °C. 
 Culture growing media 
The following media have been used for BL21/Rosetta growth. Sterilization 
was achieved in autoclave and media for bacterial growth were prepared as follows 
if not otherwise specified. Selective media were prepared adding chloramphenicol, 
ampicillin or kanamycin.  
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Luria-Bertani (LB) medium 
For 1 L final volume: 
 
M9 medium 
The M9 medium is used to achieve uniform 15N isotope incorporation in proteins. 
This medium is prepared as follows: 
For 1 L final volume: 
 
M9 salts (5X) 
For 1L final volume:   
 
Compound Quantity
Tryptone 10 g
Yeast Extract 5 g
NaCl 10 g
pH was adjusted to 7.0 after sterilization, antibiotic was added
Compound Quantity
M9 salts 200 ml
MgSO 4 2 mM
ZnSO 4 0.1 mM
CaCl 2 0.01 mM
Glucose 4%
Tiamine 1 ng/ml
NH 4 Cl* 1g 
Sterile Water up to volume
Compound Quantity
Na 2HPO 4 33,9 g
KH 2PO 4 15 g
NaCl 2.5 g
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 Protein expression and cell lysis 
The expression of unlabeled proteins was achieved by adding 10 ml of the 
starter culture to 1 liter of LB medium, then incubated in a shaker at 37 °C till an 
OD600 value of 0.6/0.7 was reached. Protein expression was induced adding        
Isopropyl-β-D-1-thiogalactopyranoside (IPTG) at a final concentration of 0.5 mM 
and leaving the culture in the shaker at the best temperature and time (Table below) 
found in the preliminary protein expression evaluation. 
 Time Temperature 
Tau4RD 5h 37 °C 
His-UB Over night 20 °C 
His-E1 5h 37 °C 
GST-E2N Over night 20 °C 
GST-CHIP Over night 20 °C 
 
After a centrifugation step at 10000g for 15 minutes, the pellet was resus-
pended in 2.5 ml/g of lysis buffer (Table A) and sonicated at the maximum soni-
cation power for 7 cycles of 1 minute (except for the enzyme where we add more 
lysozyme), alternating the sample sonication time to an equal period on ice. The 
lysate was then centrifuged for 20 minutes at 10000 g at 4 °C and the supernatant 
solution was collected. The supernatant, containing the soluble protein fraction, was 
then processed for the purification. M9 medium was used for expression of 15N 
labelled proteins and the same purification protocol was performed. 
 
Table A: Recipes of Lysis Buffer
Lysis buffer GST-Chip, GST-E2N
20 mM TrisHCl, pH 7.6
150 mM NaCl
1X Protease Inhibitor
Triton X-100 0.05% (v/v)
PMSF 100mM
Lysozyme 0.4 mg/ml
Dnase 1 (20 µg/ml)
MgCl2 10 mM
Lysis buffer His-Ub, His E1
20 mM TrisHCl, pH 7.6
1X Protease Inhibitor
Triton X-100 0.05% (v/v)
PMSF 100mM
Lysozyme 0.4 mg/ml
Dnase 1 (20 µg/ml)
MgCl2 10 mM
Lysis buffer Tau4RD
20 mM TrisHCl, pH 7.6
50 mM NaCl
1X Protease Inhibitor
PMSF 100mM
Lysozyme 0.4 mg/ml
Dnase 1 (20 µg/ml)
MgCl2 10 mM
EDTA 0.5 mM
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3.4 Protein and enzyme purification 
§ Tau4RD 
The lysate was boiled at 100 °C for 10 min and then was centrifuged for 20 
min at 10000 g at 4 °C. The soluble part was filtered and loaded onto a SP column, 
preequilibrated with Tris 20 mM, NaCl 25 mM buffer. The elution was made with 
a gradient of NaCl from 50 mM to 1 M in Tris 20mM buffer. 
 
§ His-Ubiquitin and His-E1 
The lysate was centrifuged, and the soluble part extract was filtered and 
loaded onto Ni2+ charged-chelating Sepharose (GE Healthcare), preequilibrated 
with Tris 20 mM, NaCl 50 mM buffer. The elution was made with a gradient of 
imidazole from 50 to 500 mM in Tris 20 mM, NaCl 0.5 M buffer. 
 
§ GST-CHIP and GST-E2N 
The lysate was centrifuged, and the soluble part extract was filtered and 
loaded onto Glutathione Sepharose beads (Molecular Probes, 10 ml bead suspen-
sion per liter culture) preequilibrated with PBS buffer, pH 7.4. Unbound proteins 
were washed out with 6-8 bed volumes of PBS buffer, and the fusion protein was 
eluted with 50 mM Tris pH 8, 10 mM glutathione. 
 
Prior to storage, all protein samples were than concentrated using centrifugal filter 
units (Millipore) at the proper concentration (~ 0.5 mM). Then they were frozen 
with liquid nitrogen and stored at - 20 °C. 
All samples for NMR measurements were buffer exchanged into a buffer suitable 
for NMR Experiments, in our case we use Potassium Phosphate 10 mM pH 6.8.  
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 Chromatography resins and columns 
Ion exchange chromatography resin: SP Sepharose FastFlow (GE 
Healthcare) with cationic exchanger has been used. 
10 ml resin was then poured into a XK 16/20 (GE Healthcare) column and exten-
sively washed 20 mM TrisHCl, 50 mM NaCl, pH 7.6 as running buffer. The cleared 
cellular lysate was loaded directly into the column and washed with 2 column vol-
umes of running buffer and eluted with a NaCl gradient (0-1 M). Fractions of 2 ml 
were collected and analyzed by SDS-PAGE. After use the resin was regenerated 
according to the manufacturer’s instructions. 
Nickel affinity chromatography: Chelating Sepharose, when charged with 
Ni2+ ions, selectively binds to proteins if complex forming amino acid residues, in 
particular histidine, are exposed on the protein surface. The matrix Chelating Se-
pharose Fast Flow (Amersham Biosciences), which is able to bind metal cations 
around neutral pH values, was packed into a XK 16/20 column (GE Healthcare). 
First the resin was charged with Ni2+ using 1-2 volumes of a solution of 0.25 M 
NiSO4, then the equilibration was achieved with 5 volumes of 20 mM Tris-HCl pH 
7.6, 0.5 M NaCl, 10 mM imidazole (binding buffer). The protein elution was per-
formed applying an imidazole gradient from 10 mM to 0.5 M, exploiting the ability 
of this compound to compete with the His6-tag for Ni2+ binding. Fractions of 2 ml 
were collected and analyzed by SDS-PAGE. 
Glutathione Sepharose chromatography resin: 10 mL of Glutathione Se-
pharose resin (GE Healthcare) were packed in a XK 16/20 (GE Healthcare) column. 
The resin was first washed with 10-20 volumes of mQ water and successively with 
20 mM Tris-HCl pH 7.6. The protein elution was performed adding 10 mM Gluta-
thione in the buffer, at pH 8. Fractions of 2 ml were collected and analyzed by SDS-
PAGE. 
 SDS-PAGE 
Protein purity was evaluated using Sodium Dodecyl Sulphate Polyacryla-
mide Gel Electrophoresis (SDS-PAGE). Every protein sample (10 µl) was heated 
at 95 °C for 5 minutes after the addition of 5 µl of reducing loading buffer. Samples 
were loaded into a separate well of a discontinuous 10% or 17% polyacrylamide 
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gel together with 5 μL of molecular weight marker (GE Healthcare) loaded in a 
separate well internal referencing and to identify the proteins of interest after sepa-
ration. Gels were run at 180 V for approximately one hour until the bromophenol 
blue exits the running gel. After running the gels were immersed in the staining 
solution for 20 minutes and de-stained with bidistilled hot water. 
Reducing loading buffer 
 
Polyacrylamide gel 
Stacking gel solution 
For a final 2 ml 
 
Compound Quantity
Tris-HCl pH 6.8 50 mM
DTT 100 mM
SDS 2%
glycerol 10%
Bromophenol blue 0.10%
Compound Quantity
Acrylamide mix
(30% stock solution) 5%
Tris-HCl pH 6.8
(1M stock solution) 125 mM
SDS (10% stock solution) 0.10%
Ammonium persulfate
(10% stock solution) 0.10%
TEMED 0.10%
Water up to volume
 53 
Running gel solution 
For a final 5 ml at 10 or 17% of acrylamide 
 
Running solution 
 
Staining solution 
For a final 1L: 
 
Compound 10% 17%
Acrylamide mix
(30% stock solution) 10% 17%
Tris-HCl pH 8.8
(1.5M stock solution) 0.39 mM 0.39 mM
SDS (10% stock solution) 0.10% 0.10%
Ammonium persulfate
(10% stock solution) 0.10% 0.10%
TEMED 0.04% 0.04%
Water up to volume up to volume
Quantity
Compound Quantity
Tris-HCl pH 8.3 25 mM
glycine 192 mM
SDS 0.10%
Compound Quantity
Ethanol 50%
Acetic Acid 20%
Coomassie Brilliant Blue 
(R350) 3 g/L
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Estimation of protein concentration 
The absorbance at a wavelength of 280 nm was detected using Nanodrop spectrom-
eter. Protein concentration (c) was calculated from the Beer-Lambert equation: 
Abs = ε × l × c  
A theoretical extinction coefficient at a wavelength of 280 nm measured in water 
(ε 280 nm) was estimated for each construct using the ProtParam Tool from the 
Expasy Tools server (http://www.expasy.ch/tools/protparam.html). 
3.5 Tau and Ubiquitin Interaction 
 In vitro Ubiquitination Assay 
In vitro ubiquitination reactions were carried out in 50 mM Tris-HCl buffer, pH 8, 
with 5 mM ATP, 5 mM MgCl2 and 3 mM tris(2-carboxyethyl)phosphine hydro-
chloride (TCEP). All enzymes and substrate were used as follow: 
 
His-E1 1 µM 
GST-E2N 10 µM 
GST-CHIP 10 µM 
His-Ubiquitin 70 µM 
Tau4RD 35 µM 
 Purification 
To purify Tau4RD ubiquitinated by CHIP, a large volume of ubiquitination reaction 
was prepared (4 mL), using Tau4RD and His-Ubiquitin at a concentration of 110 
and 140 μM, respectively. The reaction was incubated at 37 °C for 5 hours. Thus, 
the reaction was stopped and heated at 70 °C for ~ 15 min, in order to remove all 
enzymes from the solution. After centrifugation, the unreacted ubiquitin was re-
moved, performing a SP-ion exchange chromatography. Finally, ubiquitinated 
Tau4RD was separated from unreacted Tau4RD by IMAC, taking advantage of the 
His6-tag on Ubiquitin. 
 55 
 Thioflavin-T Assay 
The kinetic of aggregation was monitored with Thioflavin-T assay. The 0.01 mM 
of samples were diluted in the aggregation buffer: in 20 mM NaPi, 50 mM NaCl, 
pH 7.4, with 5 mM DTT, 0.02% NaN3 and protease inhibitors with EDTA, with the 
addition of 0.01 mM of heparin. Samples for ubiquitin, Tau4RD, Tau4RD in the 
presence of ubiquitin at 1:1 molar ratio, and Tau4RD ubiquitinated by CHIP were 
incubated in presence of 0.01 mM Thioflavin-T in a 96-well dark plates. The assay 
was carried out in a plate reader (FLUOstar Omega; BMG LABTECH) at 30 °C for 
72 hours with cycles of 60 seconds of shaking (900 rpm, double-orbital) and 14 
minutes of rest throughout the incubation. Thioflavin-T (ThT) fluorescence meas-
urements (mean [slit width (SD)] excitation, 450 [10] nm; mean emission, 480 [10] 
nm [bottom read (reading the fluorescence signal from the bottom to the top of the 
well)]) were taken every 15 minutes. Proteins were filtered through a 100 kDa cut-
off filter (Sartorius) before starting the aggregation to remove pre-existing large 
oligomers and fibrils. Error bars of ThT curves correspond to standard deviations 
of at least three independent experiments. 
 Atomic Force Microscopy Measurements 
Solutions of 0.05 mM Tau4RD diluted in the aggregation buffer (as describe above) 
were incubated at 37 °C without agitation for 48 hours, using heparin at 1:1 molar 
ratio as aggregation initiator. 5 mM DTT was included only for Tau4RD and 
Tau4RD ubiquitinated by CHIP. After incubation, the buffer of protein samples 
was exchanged to mQ H2O by filtration with a 100 kDa cut-off filter (Sartorius).  
Samples were then diluted in water to optimal concentration for AFM measurement 
(5 – 25 µM). About 20 µL of samples were deposited on freshly cleaved mica and 
allowed to dry in air. AFM images were acquired with a NT-MDT Solver Pro mi-
croscope, (Zelenograd, Moscow, RU), with single crystal silicon-antimony doped 
probe and a gold coated base (NSG-01 from NT-MDT) used in semi-contact mode. 
The hysteresis of the instrument was adjusted by a software correction of the data 
using calibration grid (TGQ1 from NT-MDT) before analysis. Images were pro-
cessed and analyzed with the Gwyddion software 169. 
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3.6 Tau and Lipids Interaction 
 Lipids preparation 
Sodium Oleate (O7501): a stock solution of ~ 48 mM in mQ H2O was pre-
pared, heated at 25 °C for ~ 10 minute and spinned. Then the solution was filtered 
with a 0.02 nm diameter filter (Anotop 10 plus Whatman).  
For the experiments the sample was diluted at the final concentrations of 2 or 3 mM 
in H2O and stored at RT. 
Sodium Arachidonate (SML1395): in order to prevent the fatty acid oxi-
dation, all the stock solutions were prepared under nitrogen flux in a glovebox. The 
powder was dissolved in H2O to a final concentration of 15 mM in Wheaton glass 
serum bottle (Z113948) and then stored at -20 °C. 
 Dynamic Light Scattering measurements (DLS) 
The presence of micelles was checked using dynamic light scattering 
(DLS). DLS measurements were performed with a Zetasizer Nano ZS instrument 
(Malvern Instruments, USA) operating at λ = 633 nm with backscatter detection at 
173°. The samples were allowed to equilibrate for 5 min at the measurement tem-
perature of 25 °C before starting acquisition. Measurement were repeated three time 
in order to check their repeatability. Acquisition were performed with serial dilution 
(1:2) in phosphate buffer from 2 mM to 0.01 mM. Autocorrelation function (ACF) 
was fitted in order to confirm the presence of large aggregates (micelles). 
 Tau aggregate assembly 
Aggregation was performed in 10 mM Potassium Phosphate buffer at pH 6.8 in 
presence of DTT (2 mM or 0.5 mM for CD measurements) and protease inhibitor. 
Aggregation was induced by incubation soluble of Tau4RD at the concentration of 
100 µM in volume of 0.5 ml at 37 °C with magnetic stirring in Wheaton glass serum 
bottle, respectively with heparin (molar ration of Tau to heparin 4:1170), with so-
dium oleate (molar ration of Tau to sodium oleate 1:3), with sodium arachidonate 
(1:3) 113,171. All samples were incubated for ~ 24h – 48h. The formation of aggre-
gates was monitored by SDS-PAGE. 
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 Thioflavin-T assay 
The kinetic of aggregation was monitored with Thioflavin-T assay. The samples 
were prepared in the same condition describe above and were incubated in the pres-
ence of 20 µM Thioflavin-T in a 96-well dark plate. The measurements were per-
formed in a plate reader (TECAN Infinite M200 Pro) at 37 °C for 72 hours with 
cycles of 60 seconds of shaking (250 rpm, orbital) and 14 minutes of rest throughout 
the incubation. Thioflavin-T (ThT) fluorescence measurements (mean [SD] excita-
tion, 450 nm; mean emission, 480 nm [bottom read]) were taken every 15 minutes. 
Proteins were filtered through a 100 kDa cut-off filter (Sartorius) before starting the 
aggregation to remove pre-existing large oligomers and fibrils. Error bars of ThT 
curves correspond to standard deviations of at least four independent experiments. 
 Circular dichroism (CD) spectroscopy 
CD spectroscopy studies were performed with a Jasco 1500 spectropolarimeter 
equipped with a Peltier type thermostated cell holder. Far-UV spectra (190–260 
nm) were recorded at 25 °C at a scan rate of 50 nm min-1, a bandwidth of 1 nm and 
an integration time of 2 s. Five spectra accumulations were averaged for each sam-
ple, and the spectrum of the buffer was considered as a blank and subtracted. The 
protein concentration was 6 μM in 0.1 cm cuvettes. 
 Gradient SDS-PAGE 
Gradient SDS-PAGE (10-17%) was employed on different samples under non-re-
ducing conditions to analyze the aggregates states according to the protocol defined 
by Miller co-workers172. 
5 ml of the lower concentration gel buffer (10%) are drawn into a 10 ml serological 
pipet. Using the same pipet, the higher acrylamide concentration gel buffer (17%) 
is drawn up to 10 ml final volume (Figure 22A). Then one or two air bubbles are 
flowed up into the pipet to mix the interface, and to create a linear gradient (Figure 
22B). 
When this gel solution is injected into the casting plate sandwich, the higher 
acrylamide concentration is deposited on the bottom followed by the lower 
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concentration on top. This creates a “stacked” concentration gradient with very little 
mixing of the phases at the interface. 
 
Figure 22: Example of sample acrylamide concentration differentials within the 10 ml pipet used 
to pour gel. A) The buffer with lower acrylamide concentration (10%) (light gray) is aspirated 
into pipet first followed by higher concentration (17%) (dark gray).  B) The linear gradient is then 
created when a bubble is allowed to migrate up the pipet which will cause mixing at the phase 
inter-face. When the solution is ejected into the gel sandwich, the high concentration acrylamide 
is on the bottom. 
 Atomic Force Microscopy Measurements 
After aggregation, the samples were diluted in mQ H2O for AFM measurements. 
20 μL of Tau4RD co-aggregates (5-10 μM) were deposited on freshly cleaved mica 
and allowed to dry in air. 
AFM images were acquired and analyzed as describe in previous section. 
3.7 Tau and Nanoparticles Interaction 
 Nanoparticles Preparation 
Ultrasmall Lipoic Gold Nanoparticles (Lip@AuNPs) have been purchased 
by NanoImmunotech. The solution, stored in water at a concentration of 0.6 µM 
was concentrated by several centrifugation steps (5000 rpm, 20 min, 10 repetition) 
in order to have an enough concentration allowing their utilizations, especially for 
NMR measurement. Concentrations after centrifugation have been measured by 
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UV-vis spectroscopy using a method developed by Haiss et al. (Haiss et al., 2007). 
Depending of the stock solution, the concentration varies from 9 to 12 µM. In order 
to be in the Beer-Lambert law condition, each stock was diluted by a dilution factor 
from 20 to 40. A spectral width from 300 to 800 nm was used in each case. The 
absorbance at A450 nm measured using a Nanodrop spectrometer was divided by 
the extinction coefficient (ε450nm) determined from the tables of the publication of 
Haiss at al.[14]. 
3.8 Protein NMR Analysis 
 NMR Samples Preparation 
All protein samples for NMR measurements were centrifuged at 10000g for 
10 minutes to remove any insoluble particles and the protein concentration was 
checked by measuring absorbance at 280 nm. The samples were prepared in 10 mM 
potassium phosphate aqueous buffer at pH 6.8, also containing protease inhibitors 
and 8% D2O. 
 1D and HSQC 
1D and 2D NMR experiments were acquired at 310 K and 298 K, respec-
tively, on a Bruker Avance III spectrometer, operating at 1H Larmor frequency of 
600.13MHz, equipped with a triple resonance TCI cryogenic probe. 
One-dimensional 1H-NMR experiments were acquired with a standard pulse se-
quence incorporating the excitation sculpting water suppression scheme. A total of 
128 transients were acquired over a spectral width of 12019 Hz, using a recycle 
delay of 2s. The spectra were processed applying an exponential window function 
prior to the Fourier transformation. 
Typical sensitivity enhanced 1H-15N heteronuclear single quantum coher-
ence (HSQC) were conducted by acquiring 256 complex points in the T1 dimension, 
1024 in the T2 dimension. A total number of 4-8 transients were acquired for each 
spectrum with an interscan delay of 1.2s. Standard sequence schemes with pulsed 
field gradients were used to achieve suppression of the solvent signal and 
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cancellation of spectral artifacts. Data were processed using the Bruker software 
TOPSPIN 3.2 (Bruker, Karlsruhe) and analyzed with the program NMRFAM-
SPARKY by Lee W, (https://nmrfam.wisc.edu/nmrfam-sparky-distribution/) 173. 
 Diffusion 
NMR experiments were acquired at 310 K on a Bruker Avance III spec-
trometer, operating at 1H Larmor frequency of 600.13MHz, equipped with a triple 
resonance TCI cryogenic probe. 
Pulsed field gradient NMR diffusion experiments on Tau4RD were per-
formed as using the standard Bruker ledbpgp2s1dwsse pulse sequence which im-
plements the stimulated echo and longitudinal eddy current delay schemes, as well 
as bipolar gradient pulses for diffusion. Water signal suppression was achieved by 
pre-saturation and Watergate. The gradient was set to values in the range of 5–95% 
of the maximum gradient strength. The experiment was conducted with diffusion 
and gradient times of 200 ms and 4 ms. Data were analyzed by integrating reso-
nances of the amide envelope region. 
 R2 measurements 
NMR experiments were acquired at 283 K on a Bruker SB Avance III spec-
trometer, operating at 1H Larmor frequency of 1000.13 MHz, equipped with a triple 
resonance TCI cryogenic probe. 
Nitrogen-15 transverse relaxation (15N-R2) experiments were carried out in 
gradient-selected sensitivity enhanced mode and in interleaved fashion acquiring 
2048 (1H) × 200 (15N) complex data points for each relaxation delay over spectral 
widths of 12 (1H) and 23 (15N) ppm. Optimal water signal suppression was obtained 
with optimized flip-back pulses. The recycle delay was set to 3 s and T2 relaxation 
delays were 0.016, 0.033, 0.050, 0.067, 0.084, 0.101, 0.135, 0.169, 0.203, 0.271, 
0.033, 0.203 s (23.5 T). Relaxation times were determined by fitting peak volumes 
to a two-parameter single exponential function with the software NMRFAM-
SPARKY by Lee W. (https://nmrfam.wisc.edu/nmrfam-sparky-distribution) 173. 
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 DEST measurement 
NMR experiments were acquired at 283 K on a Bruker SB Avance III spec-
trometer, operating at 1H Larmor frequency of 1000.13 MHz, equipped with a triple 
resonance TCI cryogenic probe. 
2D 15N-DEST experiments were performed using the pulse sequence avail-
able online from Dr. M. Clore (http://spin.niddk.nih.gov/clore/). The sequence was 
slightly modified to obtain an interleaved pseudo-3D version directly processable 
with spectrometer acquisition software (Bruker Topspin 3.2). 15N continuous wave 
saturation was applied for 0.9 s with field strengths of 0 Hz (reference) and 350 Hz. 
Saturation was applied at 17 offsets distributed symmetrically around 0 Hz (35, 20, 
10, 5, 4, 2, 1, 0.5, 0, -0.5, -1, -2, -4, -5, -10, -20, -35 kHz at 23.5 T). Acquisition 
times were 127 ms (1H) and 23 ms (15N) at 23.5 T. 16 transients were collected per 
free induction decay in the indirect dimension and an interscan delay of 1.3 s was 
used. A 2.1 ms (23.5 T) IBURP2 pulse was applied to achieve amide proton decou-
pling. Water flip-back pulses were used for optimal water suppression. All of the 
spectra were processed with Topspin 3.2 (Bruker, Karlsruhe), while peak intensities 
were analyzed and quantified with the program NMRFAM-SPARKY by Lee W. 
(https://nmrfam.wisc.edu/nmrfam-sparky-distribution) 173. 
DEST experiments were analyzed with DESTfit by Fawzi N.L. 
(http://spin.niddk.nih.gov/clore/Software/software.html) 162. 
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4 Results and Discussion 
4.1 Semisynthetic and enzyme-mediated conjugate preparations illumi-
nate the ubiquitination-dependent aggregation of protein Tau 
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In the brain of individuals with Alzheimer's disease, the regulatory protein 
ubiquitin is found conjugated to different lysine residues of protein Tau assembled 
into pathological paired helical filaments. To shed light on the hitherto unexplored 
ubiquitination-linked conformational transitions of Tau, the availability of in vitro 
ubiquitin conjugation methods is of primary importance. In our work, we focused 
on the four-repeat domain of Tau and assembled an enzymatic machinery formed 
by UBE1, Ubc13, and CHIP enzymes. The enzymatic reaction resulted in mon-
oubiquitination at multiple sites, reminiscent of the ubiquitination pattern observed 
in vivo. We further exploited chemo-selective disulfide coupling reactions to con-
struct three Tau regio-isomers with site-specific monoubiquitination. Protein aggre-
gation experiments revealed that the multiple enzyme-derived products were unable 
to convert into amyloid fibrils, while the semisynthetic conjugates exhibited diverse 
capability to form filaments. This study contributes novel insight into the effects of 
a key post-translational modification on aberrant protein self-assembly. 
 
Intracellular aggregates of the protein Tau, with the properties of amyloid 
fibrils, are the defining feature of a group of neurological disorders known as 
Tauopathies, which include Alzheimer’s disease (AD) [1,2]. Tau pathology has been 
recognized as a target for the development of disease-modifying therapies, the suc-
cess of which requires to acquire a deep knowledge on the multiple molecular fac-
tors that contribute to the formation of neurotoxic aggregates [3] . Tau is an intrinsi-
cally disordered protein, occurring in six distinct isoforms in adult brain and playing 
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a fundamental role in microtubule assembly and stabilization in neurons [4,5] . Under 
normal conditions, Tau function is regulated by extensive post- translational modi-
fications (PTMs), primarily phosphorylation [6,7] . Both missense mutations and ab-
errant PTMs render Tau aggregation-prone, ultimately leading to accumulation of 
insoluble filaments [7–9] . Two hexapeptide motifs in the microtubule-binding do-
main (MBD) were proposed to be implicated in the nucleation of pathological Tau 
aggregates [10] and recent cryo-EM investigations of Tau paired helical filaments 
(PHFs), isolated from AD brain, identified the polypeptide region (residues 306-
378 within the MBD) forming the core of the amyloid [11]. 
It is plausible that several distinct PTMs concur towards Tau dysfunction [9,12]. Be-
sides being hyperphosphorylated, Tau of PHFs isolated from AD brains (AD-PHFs) 
was found conjugated to ubiquitin at multiple lysine residues within the MBD [13,14]. 
In particular, the protein was reported to be monoubiquitinated at Lys254, Lys257, 
Lys311 and Lys317 [13] and modified at Lys254, Lys311 and Lys353 with polyubiq-
uitin chains [14]. It is noteworthy that monoubiquitination has been recently recog-
nized as an esteemed proteasomal targeting signal in addition to the canonical 
Lys48-polyubiquitin signal [15], suggesting an additional strategy of the ubiquitin 
proteasome system (UPS) to clear Tau aggregates. 
A thorough understanding of the determinants of PTM- associated conformational 
transitions of Tau necessitates approaches for protein modification in vitro to enable 
subsequent molecular-level characterization [16,17]. Indeed, the recent successful de-
velopment of chemical methods for the site- specific modification of Tau allowed 
to obtain unprecedented insight into the role of phosphorylation, GlcNAcylation, 
acetylation, and carboxymethylation on the self-aggregation and binding behavior 
of Tau [18–21]. However, the study of ubiquitination has lagged behind in the ensem-
ble of PTMs of Tau. 
In our work, we focused on the four-repeat region (TauK18 or Tau4RD) of the 
MBD of Tau (Figure 1A) which contains all acceptor lysine residues found ubiqui-
tinated in AD-PHFs [13,14]. For the preparation of ubiquitinated Tau4RD, we 
adopted two distinct approaches: i) enzyme-mediated conjugation employing 
CHIP, an E3 ligase able to ubiquitinate Tau in cells and found to ameliorate the 
toxic effects of various neurodegenerative disease-related proteins [22,23], ii) 
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disulphide-coupling chemistry [24-26] to produce to produce Tau regio-isomers with 
site-specific monoubiquitination in positions 254, 311, or 353, as three representa-
tives of the ubiquitinated Tau species found in vivo. By use of mass spectrometry 
we identified the sites targeted by the enzymatic machinery, we further performed 
Thioflavin-T (ThT) fluorescence aggregation assays and inspected the morphology 
of Tau aggregates using atomic force microscopy (AFM). 
In the first approach, we reconstituted enzymatic ubiquitination in vitro after select-
ing appropriate enzymes. We identified CHIP, an E3 ligase that was found to inter-
act with and ubiquitinate Tau [22,27], and that plays a key role in UPS-mediated Tau 
degradation [27,28]. CHIP can act in combination with distinct E2-conjugating en-
zymes [29] and, according to previous structural studies, it interacts with Ubc13 but 
not with its assistant Uev1a [30]. Therefore, we assembled an enzymatic machinery 
formed by CHIP, the E1 enzyme UBE1, and human Ubc13, to promote the reaction 
between Tau4RD and ubiquitin (Scheme 1A). SDS-PAGE analysis of the reaction 
products revealed a new band corresponding to a molecular weight of ~25 kDa 
(Figure 1B and S1), compatible with monoubiquitinated-Tau4RD (hereafter ub-
Tau4RD). Immunoblot analysis further confirmed the formation of this conjugate 
(Figure S2). These results demonstrate that CHIP can act in tandem with hUbc13, 
in the absence of Uev1a, to monoubiquitinate Tau in vitro. 
To identify the ubiquitinated sites, we carried out mass spectrometry (MS) analysis 
of trypsin-digested monoubiquitinated Tau4RD, obtained after a five-hours conju-
gation reaction. The analysis (Table 1 and SupportingDataSheet1) revealed that 
ubiquitination occurred on nine out of the twenty lysine residues present in 
Tau4RD. The nine sites are distributed across the four repeats (Figure 1C), however 
with greater prevalence in R2. Interestingly, after an overnight reaction the number 
of distinct sites of modification increased to twelve (Figure S3, TableS1, Support-
ingDataSheet2), matching almost completely the ubiquitinated sites found in Tau 
samples isolated from mouse [6]. Notably, CHIP-mediated ubiquitination occurred, 
among others, at Lys311 and Lys353, which are two sites found ubiquitinated in 
human brain filaments [13,14]. 
To investigate the effect of enzymatic ubiquitination on Tau filaments assembly, 
the ubiquitinated protein was first purified from unconjugated components by 
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affinity chromatography exploiting a His6-tag placed at the ubiquitin N-terminus 
(Figure S1). Aggregation kinetics experiments were then performed, based on a 
ThT assay. Unmodified Tau4RD exhibited a rapid increase in filaments formation 
(Figure 1D): the fluorescence signal displayed a typical sigmoidal growth profile 
characterized by a lag phase of ~8 hours and a plateau phase starting at ~16 hours. 
In contrast, the fluorescence signal measured on the ub-Tau4RD sample displayed 
a non-sigmoidal growth profile with modest increase in intensity over the duration 
of the experiment. This marked difference appears to reflect a reduction in the rates 
of elongation and secondary nucleation which are two key molecular processes 
governing fibrillation [31]. Thus, the data suggest that CHIP-mediated ubiquitination 
of Tau4RD, which results in a set of monoubiquitinated products, strongly inter-
feres with Tau fibril formation. To confirm that the observed inhibitory effect was 
indeed caused by the covalent modification of Tau4RD, we performed a control 
experiment with unconjugated Tau4RD and His6-ubiquitin. Interestingly, this pro-
tein mixture exhibited similar aggregation kinetics as unmodified Tau, excluding 
that the sole presence of ubiquitin could interfere with fibril formation. 
The morphology of the aggregated samples was analyzed by AFM. Unmodified 
Tau4RD was found to form mature filaments, however only small aggregates of 
10-40 nm in height and 150-350 nm in length were observed for ub-Tau4RD (Fig-
ure 1E). The latter species were not reactive with the A11 antibody (Figure 1F) 
which recognizes prefibrillar oligomers of a number of different proteins [32], in-
cluding Tau4RD. 
Together, these findings indicate that the unresolved mixture of monoubiquitinated 
Tau isomers had a strong inhibitory effect on the formation of prefibrillar and fila-
mentous structures. Notably, several modified sites fall within the 272-330 region 
which constitutes the core of heparin-induced Tau filaments [33]. Thus, the attach-
ment of a bulky macromolecule to those sites appears to cause steric hindrance, 
preventing the formation of an ordered cross-β/β-helix structure. 
The lack of site-specificity of the CHIP-based ubiquitination reaction prevents us 
from understanding the role of each ubiquitinated site in the mechanism of Tau 
aggregation. To overcome this limitation, we sought to produce Tau proteins ho-
mogenously ubiquitinated at unique sites. In this second approach, we adopted an 
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effective semisynthetic method already successfully applied to obtain ubiquitin-
modified substrates [24,26]. The conjugation between ubiquitin and Tau was based 
on a disulfide-forming reaction between a cysteine residue placed at a desired po-
sition on Tau and a ubiquitin molecule modified with a C-terminal thiol (Scheme 
1B). Since Tau4RD contains two native cysteines, we first produced the 
C291A/C322ATau4RD double mutant (hereafter Tau4RDDC) and then introduced 
a single cysteine in place of either Lys254, Lys311, or Lys353. We finally produced 
three monoubiquitinated Tau4RD isomers with linkages in those positions (hereaf-
ter ub-Tau4RD(254), ub-Tau4RD(311), and ub-Tau4RD(353)) (Figures 2A and 
S4-S8) as representatives of the ubiquitinated Tau species found in AD-PHFs. 
The impact of ubiquitination at three different sites (occurring in three distinct re-
peats) on the aggregation kinetics of Tau was then evaluated in comparison with 
the unconjugated cysteine- free protein. The ThT assay (Figure 2B) and AFM anal-
ysis (Figure 2C) showed that Tau4RDDC retained the ability to form filaments, in 
agreement with previous data on cysteine-free Tau variants [34,35]. The formation of 
fibrils by Tau4RDDC increased rapidly over time with a sigmoidal trend and a lag 
time shorter than 4 hours. Interestingly, the three ubiquitinated derivatives exhib-
ited different behavior. The aggregation kinetics of ub-Tau4RD(254) and ub-
Tau4RD(353) followed a sigmoidal trend that suggested the formation of cross-β 
structures. However, with a lag time of ~8 hours, the aggregation process was mark-
edly slowed down compared to that of Tau4RDDC. AFM images further indicated 
the presence of short filaments (Figure 2C). Instead, the ThT signal of the ub-
Tau4RD(311) sample increased with an almost linear time-dependence, suggesting 
that ubiquitination at this site strongly interferes with the conformational transitions 
that progress towards amyloid formation. Short sticks of 6-12 nm in height and 0.1-
1 μm in length were formed (Figure 2C) and were not immunoreactive with the 
A11 antibody (Figure 2D). On the contrary, A11 recognized the ub-Tau4RD(254) 
and, to a lesser extent, the ub-Tau4RD(353) aggregates (Figure 2D). 
Differences in the aggregation kinetics profiles of the three ubiquitin-Tau conju-
gates reflect changes at the level of the microscopic aggregation process: our data 
indicate that modification at Lys254 and Lys353 slows down the aggregation but 
permits the formation of filaments. Accordingly, the two conjugates were found to 
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produce A11-positive oligomers and short filaments detected by AFM. Notably, the 
two sites fall outside the 272-330 region forming the core of filaments [33], implying 
that attached ubiquitin molecules were too distant to determine steric hindrance 
against filament assembly. Both the aggregation kinetics experiments, and AFM 
analysis showed instead that ubiquitination in position 311 inhibited the formation 
of filaments more strongly: the small aggregates observed by AFM were indeed 
unable to elongate and lacked an A11- reactive epitope. The fact that Lys311 is 
located within the PHF motif of the R3 domain, which becomes part of the ordered 
core of heparin-induced [33] and AD-brain Tau filaments [11], explains why the pres-
ence of a bulky modifier at this site makes Tau unable to convert to cross-β/β-helix 
structures. Based on this consideration, we speculate that the ubiquitinated Lys311 
found in AD-PHFs may originate from a modification event that follows the for-
mation of the fibrils core. In conclusion, we have successfully applied enzyme-
based and semisynthetic methods to ubiquitinate protein Tau. We demonstrated for 
the first time the possibility to use the CHIP ligase for the ubiquitination of Tau in 
vitro. The enzyme-based reaction produced a mixture of monoubiquitinated Tau 
isomers, reminiscent of the modifications observed in vivo, which were resistant to 
fibril formation. We used semisynthesis to obtain single monoubiquitinated Tau         
regio-isomers with which we could clarify the impact of the specific ubiquitination 
sites in Tau fibrillogenesis. Ubiquitination is an important PTM playing critical 
roles in Tau degradation and in neurodegeneration. By use of a combination of 
preparation procedures we have expanded our capability to interrogate the effects 
of ubiquitin modification at the molecular level and made a step forward in under-
standing the complex PTM-linked conformational transitions of amyloidogenic 
proteins. 
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 Figures 
 
Figure 1: A) Schematic representation of full-length Tau (TauFL) sequence showing domains 
organization; the red boxes label the hexapeptide PHF motifs; ubiquitinated sites found in AD 
brains are visualized on the top. B) SDS-PAGE showing enzymatic ubiquitination of Tau4RD 
after incubation at 37 °C for 5 hours. C) Scheme of ubiquitinated sites in Tau4RD upon enzymatic 
reaction identified by MS; filled symbols represent ubiquitinated sites in AD-PHFs. D) Kinetics 
of protein aggregation followed by ThT-fluorescence; the aggregation assay was done at 30 °C 
for ubiquitin, Tau4RD, Tau4RD in the presence of ubiquitin at 1:1 molar ratio and ub-Tau4RD. 
E) AFM images of Tau4RD and ub-Tau4RD after 48 hours of incubation at 37 °C under static 
condition (scale bar: 2 µm). F) Dot Blot of samples in panel E, probed with the A11 antibody; 
proteins were also stained with Ponceau. 
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Scheme 1: A) Enzymatic cascade leading to ubiquitin (Ub) conjugation of Tau4RD: UBE1 acti-
vating, Ubc13 conjugating, CHIP ligase enzymes. B) Semisynthetic disulfide-based site-specific 
ubiquitination of Tau4RD. 
 
Figure 2: A) SDS-PAGE showing the purified site-specific monoubiquitinated Tau regio-iso-
mers; incubation with dithiothreitol cleaved the ub-Tau disulfide linkage as expected; the schemes 
of Tau4RD modified at specific positions are shown. B) Kinetics of protein aggregation followed 
by ThT-fluorescence; aggregation experiments were carried out on Tau4RDDC, ub-
Tau4RD(254), ub-Tau4RD(311), and ub-Tau4RD(353) at 30 °C. C) AFM images of the same 
proteins after 48 hours of incubation at 37 °C under static condition (scale bar: 2 µm). D) Dot 
Blot of samples in C, probed with the A11 antibody; proteins were also stained with Ponceau. 
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Table 1: Modified peptides identified by MS analysis on ub-Tau4RD conjugate 
obtained by enzymatic reaction at 37 °C for 5 hours.[a] 
 
[a] For each identified K-ε-GG peptide obtained with trypsin digestion of the sample the table 
reports: the sequence of peptides containing ubiquitinated lysines (indicated as K(GG)); K(GG) 
peptide position numbered according to the human Tau 441 isoform; Posterior Error Probability 
(PEP). 
  
 71 
  References 
 [1] V. M.-Y. Lee, M. Goedert, J. Q. Trojanowski, Annu. Rev. Neurosci. 2001, 24,1121–1159. 
 [2] E. Mandelkow, Trends Cell Biol. 1998, 8, 425–427. 
 [3] E. E. Congdon, E. M. Sigurdsson, Nat. Rev. Neurol. 2018, 14, 399–415. 
 [4] M. D. Weingarten, A. H. Lockwood, S. Y. Hwo, M. W. Kirschner, Proc. Natl. Acad. Sci. U. 
S. A. 1975, 72, 1858–1862. 
 [5] J. Avila, J. J. Lucas, M. Pérez, F. Hernández, Physiol. Rev. 2004, 84, 361–384.  
 [6] M. Morris, G. M. Knudsen, S. Maeda, J. C. Trinidad, A. Ioanoviciu, A. L. Burlingame, L. 
Mucke, Nat. Neurosci. 2015, 18, 1183–1189. 
 [7] L. Martin, X. Latypova, F. Terro, Neurochem. Int. 2011, 58, 458–471. 
 [8] Y. Wang, E. Mandelkow, Nat. Rev. Neurosci. 2016, 17, 22–35. 
 [9] C. Kontaxi, P. Piccardo, A. C. Gill, Front. Mol. Biosci. 2017, 4, DOI   
10.3389/fmolb.2017.00056. 
 [10] M. von Bergen, P. Friedhoff, J. Biernat, J. Heberle, E.-M. Mandelkow, E. Mandelkow, Proc. 
Natl. Acad. Sci. 2000, 97, 5129–5134. 
 [11] A. W. P. Fitzpatrick, B. Falcon, S. He, A. G. Murzin, G. Murshudov, H. J. Garringer, R. A. 
Crowther, B. Ghetti, M. Goedert, S. H. W. Scheres, Nature 2017, 547, 185–190. 
 [12] M. Goedert, D. S. Eisenberg, R. A. Crowther, Annu. Rev. Neurosci. 2017, 40, 189–210. 
 [13] M. Morishima-Kawashima, M. Hasegawa, K. Takio, M. Suzuki, K. Titani,Y. Ihara, Neuron 
1993, 10, 1151–1160. 
 [14] D. Cripps, S. N. Thomas, Y. Jeng, F. Yang, P. Davies, A. J. Yang, J. Biol. Chem. 2006, 281, 
10825–10838. 
 [15] I. Livneh, Y. Kravtsova-Ivantsiv, O. Braten, Y. T. Kwon, A. Ciechanover, BioEssays News 
Rev. Mol. Cell. Dev. Biol. 2017, 39, DOI 10.1002/bies.201700027. 
 [16] C. D. Spicer, B. G. Davis, Nat. Commun. 2014, 5, 4740. 
 [17] M. Broncel, E. Krause, D. Schwarzer, C. P. R. Hackenberger, Chem. - Eur. J. 2012, 18, 2488–
2492. 
 [18] O. Reimann, C. Smet-Nocca, C. P. R. Hackenberger, Angew. Chem. Int. Ed. 2015, 54, 306–
310. 
 [19] S. Schwagerus, O. Reimann, C. Despres, C. Smet-Nocca, C. P. R. Hackenberger, J. Pept. Sci. 
2016, 22, 327–333. 
 [20] M. Haj-Yahya, H. A. Lashuel, J. Am. Chem. Soc. 2018, 140, 6611– 6621. 
 [21] D. Ellmer, M. Brehs, M. Haj-Yahya, H. A. Lashuel, C. F. W. Becker, Angew. Chem. Int. Ed. 
2019, 58, 1616–1620. 
 [22] L. Petrucelli, Hum. Mol. Genet. 2004, 13, 703–714. 
 [23] H. Shimura, D. Schwartz, S. P. Gygi, K. S. Kosik, J. Biol. Chem. 2004, 279, 4869–4876. 
 [24] C. Chatterjee, R. K. McGinty, B. Fierz, T. W. Muir, Nat. Chem. Biol. 2010, 6, 267–269. 
 [25] J. Chen, Y. Ai, J. Wang, L. Haracska, Z. Zhuang, Nat. Chem. Biol. 2010, 6, 270–272. 
 72 
 [26] F. Meier, T. Abeywardana, A. Dhall, N. P. Marotta, J. Varkey, R. Langen, C. Chatterjee, M. 
R. Pratt, J. Am. Chem. Soc. 2012, 134, 5468–5471. 
 [27] S. Hatakeyama, M. Matsumoto, T. Kamura, M. Murayama, D.-H. Chui, E. Planel, R. Takaha-
shi, K. I. Nakayama, A. Takashima, J. Neurochem. 2004, 91, 299–307. 
 [28] M. J. Lee, J. H. Lee, D. C. Rubinsztein, Prog. Neurobiol. 2013, 105, 49– 59. 
 [29] S. E. Soss, Y. Yue, S. Dhe-Paganon, W. J. Chazin, J. Biol. Chem. 2011, 286, 21277–21286. 
 [30] M. Zhang, M. Windheim, S. M. Roe, M. Peggie, P. Cohen, C. Prodromou, L. H. Pearl, Mol. 
Cell 2005, 20, 525–538. 
 [31] P. Arosio, T. P. J. Knowles, S. Linse, Phys. Chem. Chem. Phys. PCCP 2015, 17, 7606–7618. 
 [32] R. Kayed, E. Head, J. L. Thompson, T. M. McIntire, S. C. Milton, C. W. Cotman, C. G. Glabe, 
Science 2003, 300, 486–489. 
 [33] W. Zhang, B. Falcon, A. G. Murzin, J. Fan, R. A. Crowther, M. Goedert, S. H. Scheres, eLife 
2019, 8, e43584. 
 [34] E. Akoury, M. Pickhardt, M. Gajda, J. Biernat, E. Mandelkow, M. Zweckstetter, Angew. 
Chem. Int. Ed Engl. 2013, 52, 3511–3515. 
 [35] Y. K. Al-Hilaly, S. J. Pollack, D. M. Vadukul, F. Citossi, J. E. Rickard, M. Simpson, J. M. D. 
Storey, C. R. Harrington, C. M. Wischik, L. C. Serpell, J. Mol. Biol. 2017, 429, 3650–3665. 
  
 73 
 Supplementary information 
Experimental Procedures: 
Reagents  
Cysteamine, Tris(2-carboxyethyl)phosphine, 2,2′-Dithiobis(5-nitropyridine), Thio-
flavin-T, IPTG, Heparin (H3393), dithiothreitol, NH4HCO3, acetonitrile, formic 
acid, methyl methanethiosulfonate, were purchased from Sigma. 
 
Protein expression and purification 
E. coli codon-optimized human Tau cDNA sequence was purchased from Eurofins 
Genomics. Tau4RD (spanning residues Q244-E372 plus initial Met) was cloned 
into a pET22 vector via NdeI-BamHI sites with a stop codon to avoid insertion of 
a C-terminal histidine-tag. N-terminal histidine6-tag Tau4RD was cloned into a 
pET15 vector via NdeI-BamHI sites. Tau4RD mutants C291A, C322A; C291A, 
C322A, K254C; C291A, C322A, K311C and C291A, C322A, K353C were ob-
tained by site-directed mutagenesis. While the last two mutants could be easily pro-
duced in pET22 vector, the triple mutant C291A, C322A, K254C Tau4RD was ob-
tained in pET15 only. 
All Tau4RD variants were expressed in BL21 (DE3) cells grown in LB medium, at 
37 °C for 5 hours with 0.5 mM IPTG. Protein purification was achieved either by 
thermal treatment of the soluble bacterial extract (80 -100 °C) and SP-ion exchange 
chromatography or by immobilized nickel affinity chromatography (IMAC) for his-
tidine-tag proteins. Where necessary, the histidine tag was removed by thrombin 
and a second step of IMAC. 
Wilde-type human ubiquitin was produced as previously described(1). 
N-terminal histidine6-tagged ubiquitin was cloned into a pET15 vector via NdeI-
BamHI sites and expressed in E. coli Rosetta (DE3) cells grown in LB medium, at 
20 °C overnight with 0.5 mM IPTG. His6-tagged ubiquitin was purified by IMAC 
according to standard protocols. 
Ubiquitin used in the semisynthetic reaction was produced with the GyrA intein 
and the chitin binding domain fused at its C-terminus. Plasmid ptXB1 encoding for 
this construct was kindly provided by Prof. David Fushman, University of Mary-
land (USA). The fusion protein was produced in BL21 (DE3) cells at 37 °C 
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overnight in auto-inducing medium and purified by affinity chromatography using 
the chitin resin (NEB) in Tris-HCl 20 mM at pH 7.5, NaCl 200 mM, EDTA 1 mM, 
Triton 0.05%. Elution of ubiquitin bearing an aminoethanethiol C-terminal group 
(Ub-SH) was obtained by incubating the clean fusion protein attached to the chitin 
resin with Tris-HCl 20 mM, NaCl 200 mM, EDTA 1 mM, cysteamine, and Tris(2-
carboxyethyl)phosphine (TCEP) 50 mM at pH 7.5 for 24 h. Ub-SH was further 
purified by a superdex-75 gel filtration column. The protein was verified by ESI-
MS (Figure S4), which yielded an observed mass value of 8624.6 Da (expected: 
8625 Da). Human E1 (UBE1) with an N-terminal histidine tag was produced as 
previously described (2). The pET21 plasmid encoding UBE1 gene was a gift from 
Cynthia Wolberger (Addgene plasmid #34965; http://n2t.net/addgene:34965; 
RRID:Addgene_34965(3)). 
HUbc13 (human E2N, UniProtKB P61088) and human E3 ubiquitin-protein ligase 
CHIP (UniProtKB Q9UNE7) were both amplified from a HEK293 cells cDNA li-
brary and cloned into a pGEX4T1 vector via EcoRI/BamHI sites. Both enzymes 
were produced with an N-terminal GST-tag in E. coli Rosetta (DE3) cells in LB 
medium at 20 °C overnight with 0.4 mM IPTG and purified with GSH-chromatog-
raphy by standard procedures. 
 
Activation of Ub-SH by 2,2′-Dithiobis(5-nitropyridine)  
Ub-SH was activated with 2,2′-dithiobis(5-nitropyridine) (DTNP) to generate an 
asymmetric disulfide. 8 mg of DTNP were dissolved in 3 mL of acetic acid and 
then added to 1 mL of Ub-SH in mQ H2O at a concentration of 1 mg/mL. The 
mixture was incubated for 24 h at 25 °C, and then dialysed against mQ H2O. The 
resulting product, Ub-S-nitro-2-pyridinesulfenyl disulfide adduct (Ub-S-pNpys) 
was verified by ESI-MS (figure S5), which measured a mass value of 8778.5 Da 
(expected: 8779.0 Da). 
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Reaction of Ub-S-nitro-2-pyridinesulfenyl disulfide adduct with Tau4RD cysteine 
mutants 
Tau4RD cysteine mutants were incubated with a large excess of DTT. The latter 
was then removed by buffer-exchange with dialysis or desalting column prior the 
coupling reaction. 
Typically, 2 mg of Tau4RD cysteine mutant was incubated with 2 mg of Ub-S-
pNpys (twofold molar excess of activated ubiquitin) in 1 ml of 100 mM Hepes 
buffer, pH 7, for 40’ at 25 °C with continuous shaking. The reaction product was 
then purified by SP-ion exchange chromatography and verified by MALDI. We 
obtained mass values of 22637, 22353 and 22363 Da for the ubiquitin-Tau4RD 
adducts conjugated in position 254 (expected mass 22629: this value corresponds 
to a Tau mutant with an additional N-terminal GSH peptide resulting from throm-
bin-processing of an N-terminal histidine tag), 311 (expected mass 22348), and 353 
(expected mass 22348), respectively. 
 
Dot blotting 
About 3 μg of each protein sample were spotted on a PVDF membrane (Millipore). 
After blocking in TBS-T (0.1% Tween-20, 150 mM NaCl, 10 mM Tris at pH 8.0) 
with 5% (w/v) fat-free dry milk at room temperature, the membrane was washed 
three times with TBST and incubated with the anti-oligomer antibody A11 (1:2000, 
ThermoFisher) at 4 °C overnight. Membranes were washed three times with TBS-
T and incubated with the goat HRP-conjugated secondary antibody (1:10000, Ther-
moFisher) in blocking buffer for 2 hours at room temperature. After washing three 
times with TBS-T, the blot was developed with ECL reagents (Pierce) on a Chem-
iDoc imager (BioRad). 
 
Enzymatic ubiquitination 
Ubiquitination reactions were carried out in 50 mM Tris-HCl buffer, pH 8, also 
containing 5 mM ATP, 5 mM MgCl2 and 3 mM TCEP, using 1 μM His-tagged E1, 
10 μM GST-tagged Ubc13, and 10 μM GST-tagged CHIP. Ubiquitin and Tau4RD 
substrates were used at 70 and 35 μM concentration, unless otherwise specified. 
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Trypsin digestion for LC-MS/MS analysis 
SDS-PAGE bands corresponding to Tau4RD before and after the reaction with E1-
hUbc13-CHIP were excised and divided in small pieces. A digestion with trypsin 
was performed in gel according to published protocols(4) with some modifications. 
Briefly, after washing several times the gel pieces alternatively with 50 mM 
NH4HCO3 and acetonitrile (ACN), samples were dried under vacuum. 
Reduction of cysteine residues was carried out by incubating the gel pieces with 50 
µL of TCEP (2 mM in 50 mM NH4HCO3) for 1 h at 56 °C. Successively, the re-
ducing solution was discarded and gel pieces were treated with 50 µL of the alkyl-
ating agent methyl methanethiosulfonate (MMTS) (4 mM in 50 mM NH4HCO3) 
for 15 min at room temperature. The solution was discarded and the samples were 
washed with 50 mM NH4HCO3 and ACN, and dried under vacuum. 10 µL of se-
quencing grade modified trypsin (12.5 ng/µL) were added and the digestion was 
allowed to proceed overnight at 37 °C before stopping it with the addition of 1 µL 
of pure formic acid (FA). 
Peptides were extracted from the gel by several passages in 10 mM NH4HCO3, in 
50% ACN/0.1% FA and in 75% ACN/0.1% FA. Samples were finally dried under 
vacuum and stored at -20 °C until the LC-MS/MS analysis was performed. 
 
LC-MS/MS and data analysis 
The analysis was performed using an LTQ-Orbitrap XL mass spectrometer 
(Thermo Fisher Scientific) interfaced to a nano-HPLC Ultimate 3000 (Dionex – 
Thermo Fisher Scientific). Samples were dissolved in 15 µL of 3% ACN/0.1% FA 
and 3  µL were loaded into a trap column (NanoEase Symmetry300, C18, 5 µm, 
Waters) using a flow rate of 8 µL/min. Peptides were then transferred to a 10 cm 
pico-frit column (75 μm I.D., New Objective) packed in house with C18 material 
(Aeris Peptide 3.6 µm XB-C18, Phenomenex) and separated using a linear gradient 
of ACN/0.1% FA (from 3% to 40% in 20 min) with a flow rate of 250 nL/min. MS 
spectra were acquired in the Orbitrap (60000 nominal resolution) in the range 300-
1700 m/z, while MS/MS spectra were acquired in the linear ion trap. The instrument 
operated in a data-depended mode, with a cycle consisting of a full MS scan 
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followed by the MS/MS scans of the 10 most intense ions. Mono-charged ions were 
excluded from fragmentation. 
Raw data were analyzed with the software Proteome Discoverer 1.4 (Thermo Fisher 
Scientific) interfaced to a Mascot server (version 2.2.4, Matrix Science). Search 
was done against the human section of the Uniprot database. Trypsin was selected 
as digesting enzyme with up to 2 missed cleavages allowed. Peptide and fragment 
tolerance were set to 10 ppm and 0.6 Da respectively. Methyltio-cysteine was set 
as fixed modification, while methionine oxidation and Gly-Gly modification of ly-
sine residues were set as variable modifications. The algorithm percolator was used 
in combination with a search against a randomized database to assess the False Dis-
covery Rate (FDR). Results were filtered to keep into account only proteins identi-
fied with at least 2 unique peptides with high confidence (FDR ≤ 0.01). 
 
MS analysis of intermediates of semisynthesis 
ESI-MS analyses were carried out on a MicrOTOF mass spectrometer (Bruker Dal-
tonics, Bremen, Germany). Capillary voltage was – 4.5 kV, source temperature 200 
°C. Nitrogen was used both as drying and nebulizing gas (drying gas flow rate: 5 
l/min, nebulizer pressure: 6 psi). The mass spectrometer was operated in the posi-
tive ion scan mode from 50 to 3000 m/z, with acquisition scan rate of 20 spectra per 
second. 
Samples were dissolved in a mixture of ACN/water (50/50) added with 0.1 % FA 
and then directly infused into the ESI source of the TOF mass spectrometer with a 
flow of 5 μl/min delivered by a syringe pump (Cole-Parmer, Vernon Hill, IL, USA).  
External calibration was obtained by infusing for one minute at the beginning of 
each analysis a solution composed of 10 mM sodium hydroxide in isopropanol and 
0.2% FA (1:1, v/v), using seven calibration ions corresponding to the formulas 
Na(NaCOOH)x, with x ranging from 2 to 9. Data processing was fully carried out 
using Data Analysis software (Version 3.2, Bruker Daltonics). 
Maldi TOF MS analysis was performed on a Bruker Ultraflextreme MALDI-
TOF/TOF instrument (Bruker Daltonics). 
Samples were resuspended and acidified with ACN/H2O solution (30:70 (v/v) ace-
tonitrile:0.1% TFA in water) and incubated for 30 min at room temperature. The 
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resulting solution was mixed 1:1 (v/v) with the matrix Sinapinic acid (trans-3,5-
dimethoxy-4-hydroxycinnamic acid) (10 mg/ml in ACN:H2O 1:1 with 0.1% TFA), 
and then 1 µl of the sample/matrix solution was spotted in triplicate onto a Ground 
steel MALDI target plate (Bruker Daltonics), allowed to dry at room temperature.  
Mass spectra were collected from m/z 5000 to 20000 in positive linear mode and 
mass calibration was performed using a protein standard mixture composed by my-
oglobin, cytochrome C, ubiquitin I and insulin. Instrument settings were: ion source 
1: 19.93 kV; ion source 2: 18.77 kV; lens: 8.57 kV; delay time:104 ns with a scale 
factor of 800; acceleration voltage: 20 kV; number of shots: 2000 in six different 
positions for one spectrum. All the data were analysed with FlexAnalysis Software 
(Bruker Daltonics) 
 
Purification of Tau4RD ubiquitinated by CHIP 
To purify Tau4RD ubiquitinated by CHIP, a large volume of ubiquitination reaction 
was prepared (4 mL), using Tau4RD and His6-tagged ubiquitin at a concentration 
of 110 and 140 μM, respectively. After incubation at 37 °C for 5 hours, the reaction 
was stopped and heated at 70 °C for 15 minutes: this thermal treatment removes all 
the enzymes from the solution. Removal of unreacted ubiquitin was then achieved 
by SP-ion exchange chromatography. Finally, ubiquitinated Tau4RD was separated 
from unreacted Tau4RD by IMAC, taking advantage of the His6-tag on ubiquitin. 
 
Thioflavin-T aggregation assay 
Solutions of 0.01 mM Tau4RD variants in 20 mM sodium phosphate buffer at pH 
7.4 and 50 mM NaCl (with 0.02% NaN3 and protease inhibitors with EDTA) were 
incubated in the presence of 0.01 mM Thioflavin-T and 0.01 mM heparin in 96-
well dark plates in a plate reader (FLUOstar Omega; BMG LABTECH) at 30 °C 
for 72 hours with cycles of 60 seconds of shaking (900 rpm, double-orbital) and 14 
minutes of rest throughout the incubation. The aggregation assay for ubiquitin, 
Tau4RD, Tau4RD in the presence of ubiquitin at 1:1 molar ratio, and Tau4RD ubiq-
uitinated by CHIP was performed in the presence of 5 mM DTT. In the latter sam-
ples, ubiquitin carries a His6-tag at its N-terminus. Thioflavin-T (ThT) fluorescence 
measurements (mean [SD] excitation, 450 [10] nm; mean emission, 480 [10] nm 
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[bottom read]) were taken every 15 minutes. Proteins were filtered through a 100 
kDa cut-off filter (Sartorius) before starting the aggregation to remove pre-existing 
large oligomers and fibrils. Error bars of ThT curves correspond to standard devia-
tions of at least three independent experiments. 
 
Aggregation of Tau4RD variants for AFM analysis 
Solutions of 0.05 mM Tau4RD variants in 20 mM sodium phosphate buffer at pH 
7.4 and 50 mM NaCl (with 0.02% NaN3 and protease inhibitors with EDTA) were 
incubated at 37 °C without agitation for 48 hours, using heparin at 1:1 molar ratio 
as aggregation initiator. 5 mM DTT was included only for Tau4RD and Tau4RD 
ubiquitinated by CHIP. After incubation, the buffer of protein samples was ex-
changed to mQ H2O by filtration with a 100 kDa cut-off filter (Sartorius). 
 
AFM analysis 
For AFM measurements, 20 μL of Tau4RD variant aggregates (5-25 µM) in mQ 
H2O were deposited on freshly cleaved mica, and allowed to dry in air. AFM images 
were acquired with a NT-MDT Solver Pro microscope, (Zelenograd, Moscow, RU), 
with single crystal silicon-antimony doped probe and a gold coated base (NSG-01 
from NT-MDT) used in semi-contact mode. The hysteresis of the instrument was 
adjusted by a software correction of the data using calibration grid (TGQ1 from 
NT-MDT) before analysis. Images were processed and analyzed with the 
Gwyddion software. 
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 Supplementary figures and tables 
 
Figure S1. Coomassie Blue-stained SDS-PAGE showing His6-ub-Tau4RD obtained from the en-
zymatic reaction performed at 37 °C for 5 hours with UBE1, hUbc13 and CHIP. A control in the 
absence of CHIP is also reported. In the last lane, the purified His6-ub-Tau4RD, obtained after 
thermal treatment and SP-ion exchange is shown. 
 
Figure S2. Immunoblot analysis of the in vitro enzymatic ubiquitination reaction of Tau4RD 
incubated overnight at 30 °C with UBE1, hUbc13 and CHIP. The analysis was performed with 
anti-his-tag mAb in assays done with the His6-tag fused at the N-terminus of either ubiquitn or 
Tau4RD. Enzymatic reactions carried out without ATP or Tau4RD were used as controls. The 
blot revealed the presence of a new band running close to the 25 kDa marker, corresponding to 
His6-ub-Tau4RD or ub-His6-Tau4RD, that was absent in the negative controls. Bands correspond-
ing to monoubiquitinated Tau4RD are highlighted with a red asterisk. A positive band corre-
sponding to slightly larger molecular weight (close to the 35 kDa marker) could instead represent 
a diubiquitinated species of Tau4RD. Unexpectedly, we also found an immunoreactive band run-
ning between 17 and 25 kDa, which was only present when the His6-tag was on ubiquitin, and 
could be attributed to free diubiquitin chains (Ub2). The high molecular weight band close to the 
48 kDa marker that is positive to anti-his tag mAb in all lanes, could correspond to degradation 
products of His6-tagged E1. Higher molecular weight bands in the reaction with His6-ubiquitin 
could instead be assigned to ubiquitinated enzymes: indeed, those bands are not present at time 0 
and in the absence of ATP, while they show up after 15 hours and in the absence of Tau. 
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Figure S3. Scheme of ubiquitinated sites found by MS in Tau4RD upon enzymatic reaction per-
formed at 30 °C for 16 hours. Filled symbols represent ubiquitinated sites in AD-PHFs. 
 
Figure S4. ESI-MS analysis of the Ub-SH sample. The experimental mass value was 8624.6 Da 
(expected: 8625 Da). 
 
Figure S5. ESI-MS analysis of Ub-S-pNpys. The experimental mass value was 8778.5 Da (ex-
pected: 8779.0 Da). 
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Figure S6. Maldi TOF MS analysis of ub-Tau4RD(254). The experimental mass value was 22637 
Da (expected mass 22629 Da). 
 
Figure S7. Maldi TOF MS analysis of ub-Tau4RD(311). The experimental mass value was 22353 
Da (expected mass 22348 Da). 
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Figure S8. Maldi TOF MS analysis of ub-Tau4RD(353). The measured mass value was 22363 
Da (expected mass 22348 Da). 
Table S1. Modified peptides identified by MS analysis on ub-Tau4RD conjugate obtained by 
enzymatic reaction at 30 °C for 16 hours.a  
 
a For each identified  K-ε-GG peptide obtained with trypsin digestion of the sample the table 
reports: the sequence of peptides containing ubiquitinated lysines (indicated as K(GG)); K(GG) 
peptide position numbered according to the human Tau 441 isoform; Posterior Error Probability 
(PEP).  
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Table S1. M dified peptides identified by MS analysis on ub-tau4RD conjugate obtained by enzymatic 
reaction at 30 °C for 16 hours.a  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a For each identified  K-ε-GG peptide obtained with trypsin digestion of the sample the table reports: the sequence of 
peptides containing ubiquitinated lysines (indicated as K(GG)); K(GG) peptide position numbered according to the 
human tau 441 isoform; Posterior Error Probability (PEP).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peptide sequence K(GG) position  PEP 
SK(GG)IGSTENLK 259 3.69E-02 
IGSTENLK(GG)HQPGGGK 267 7.37E-5 
HQPGGGK(GG)VQIINK 274 2.51E-05 
K(GG)LDLSNVQSK 281 1.35E-8 
LDLSNVQSK(GG)CGSK 290 9.24E-4 
DNIK(GG)HVPGGGSVQIVYKPVDLSK 298 1.78E-6 
HVPGGGSVQIVYK(GG)PVDLSK 311 5.11E-11 
HVPGGGSVQIVYKPVDLSK(GG)VTSK 317 5.47E-5 
VTSK(GG)CGSLGNIHHKPGGGQVEVK 321 4.01E-9 
CGSLGNIHHK(GG)PGGGQVEVK 331 8.87E-7 
VQSK(GG)IGSLDNITHVPGGGNK 353 5.00E-8 
IGSLDNITHVPGGGNK(GG)K 369 8.16E-11 
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4.2 Unsaturated fatty acid-induced conformational transitions and aggre-
gation of the repeat domain of Tau 
The concentration and composition of Unsaturated Fatty Acids (UFAs) in the brain 
are altered with age and are associated with neurological disorders, including Alz-
heimer’s Disease. 
Several reports propose that, in these conditions, Tau protein could interact with 
free fatty acids in a micellar state [1-3]. Therefore, investigations of lipid-protein co-
assembly are necessary to deepen our understanding of both the healthy and aber-
rant action of amyloidogenic proteins, also providing the basis for the development 
of therapeutic strategies against devastating neurodegenerative diseases. 
In our work, we aimed to study the binding of Tau4RD protein to unsatu-
rated fatty acids/salts, proposed as aggregation inducers. Mostly we were interested 
in identifying the polypeptide regions involved in the interactions and detecting 
conformational transitions experienced by Tau4RD in the presence of these mole-
cules. Two of the most abundant FA (Figure 1) in the grey matter of the human 
brain were used to investigate the nature of this interaction: Arachidonic Acid 
(ARA) (20:4), a polyunsaturated fatty acid (PUFA), and Oleic Acid (OLA) (18:1), 
a monounsaturated fatty acid (MUFA), which constitutes the 45% of unsaturated 
fatty acid in the cerebral spinal fluid (CSF). 
In our work, these FAs were used in the form of micelles (Supplementary infor-
mation (SI1)) in order to mimic the elevated levels of FAs in pathological condi-
tions and to produce lipid vesicles exhibiting a negatively charged surface, pre-
dicted to interact with the positively charged Tau4RD. 
The interaction was characterized using NMR spectroscopy for the obser-
vation of lipid-induced perturbations at the single-residue level and Circular Di-
chroism (CD) measurements to monitor the perturbations at the level of secondary 
structure elements. Aggregation assays were further conducted by monitoring time-
dependent changes in Thioflavin-T fluorescence while the protein was incubated in 
the presence of UFAs. The co-aggregates were subsequently characterized in terms 
of size and morphology by SDS-PAGE and Atomic Force Microscopy (AFM). 
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 Aggregation of Tau4RD in the presence of Unsaturated Fatty Acids 
The formation of Tau4RD aggregates in the presence of ARA and OLA 
(molar ratio 1:3 P/FA) (samples prepared as described in Material and Method par-
agraph 3.6) was followed by the Thioflavin-T (ThT) fluorescence assay. The inter-
action of Tau4RD with FAs micelles exhibits an increase in fluorescence intensity 
after 2 days of incubation a 37 °C (Figure 2A and B), which continues over time 
(blue curves). In contrast, the fluorescence signals measured on the two controls, 
Tau4RD (green curves) and fatty acid (red curves) display no time-dependent in-
crease in intensity. This observation indicates that the interaction of protein and FA 
promotes the formation of ThT-positive Tau aggregates. However, at this concen-
tration and molar ratio, the fibrils formation remains less pronounced compared to 
the sample incubated with heparin, another anionic cofactor. The data collected 
show that after a few hours of incubation, the curve plateau is reached (Figure 2C). 
To analyze the co-aggregates, gradient polyacrylamide gel electrophoresis 
was performed on these samples, under non-reducing condition. Gradient poly-
acrylamide concentration was used because it can offer some advantages compared 
to fixed concentration gels [4]: 
1. Separating a wide range of protein sizes into a single gel 
2. High resolving power of distinct proteins with close molecular weights 
 
Tau4RD shows a clear and concentrated band of monomer at about 14 KDa (the 
molecular weight has been estimated based on previously run SDS-PAGE with mo-
lecular weight standards), whose intensity does not appear to decrease significantly 
over time. However, after 72 h of incubation, the presence of large oligomers was 
observed in the gel. Furthermore, the presence of insoluble protein material in the 
loading wells indicates also the formation of SDS-resistant high molecular weight 
co-aggregates. A similar pattern of bands was observed in a control sample incu-
bated with Heparin. In contrast, Tau4RD migrates as a compact band, without pre-
cipitated material in the well, showing only an increase in the formation of the di-
mers. These evidences appear in agreement with what observed in the ThT assay. 
Thus, these data suggest the ability of lipids to induce co-aggregates formation of 
Tau4RD protein. 
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 1H-NMR measurement of Tau4RD monomer depletion and transla-
tional diffusion 
In our work, we also used NMR spectroscopy to explore the protein-lipid interac-
tion. The addition of a threefold molar excess of FA to Tau4RD perturbed the pro-
tein 1H-NMR profile to very little extent: virtually no chemical shift changes were 
observed, and intensities were only slightly reduced (Figure 4). On the contrary, the 
signals of the FAs became undetectable and they did not add to the protein signals. 
Based on translational diffusion measurements, the observable protein 1H-NMR 
signals could be attributed to Tau4RD molecules which were freely diffusing in 
solution and were not part of larger aggregates (Figure S1). Thus, a small portion 
of protein molecules appeared to interact with the bulk of FAs, determining a major 
change in lipid aggregation state and/or dynamics. We note that in our aggregation 
studies, both FAs were predominantly in the micellar state (Figure S5), however, 
signals of free monomers of ARA were also observed (not shown). 
To monitor protein aggregation, 1H-NMR spectra were recorded on P/FA samples 
immediately after mixing and after 24 h or 48 h of incubation. In the presence of 
OLA, the spectrum intensity decreased by 67% after 24 h (Figure 5A), indicating 
that the population of free protein was reduced, likely due to the formation of pro-
tein-containing aggregates. Unexpectedly, the translational diffusion of the species 
observed in the spectrum did not decrease but instead was slightly faster (~10%) 
compared to that measured on the freshly prepared mixture (Figure 5B). This result 
can be likely attributed to the structural compaction induced by the formation of 
intramolecular disulfide bridges upon progressive decrease of DTT reducing activ-
ity. 
In the case of ARA, the protein spectrum displayed reduced intensity after 24 h 
(30% reduction) and after 48 h (60%) (Figure 5C). Again, it was remarkable to 
observe that the protein diffusion coefficient became larger (~20% at 48h) after 
prolonged incubation with the FA (Figure 5D). 
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 1H-15N-NMR measurements 
To better understand the conformational properties of the free Tau4RD and 
co-aggregates, HSQC spectra were recorded on protein alone and immediately after 
the addition of FAs, and after 24 h and 48 h of incubation. The spectrum of Tau4RD 
(Figure 6A) exhibits a dense cluster of cross-peaks over a narrow ppm range in 
agreement with its unfolded nature. The spectra obtained after the immediate addi-
tion of FAs are quite similar to those previously recorded in their absence (Figure 
6B and C), indicating that the conformational properties of the observable protein 
species are unchanged with respect to those of the free protein.  
As expected, the spectra obtained after 24h (data not shown) and 48h of 
incubation of the protein alone (Figure S6) are identical to those previously rec-
orded, indicating that the protein largely maintains its unfolded nature also after         
48 h of incubation. 
The spectra obtained after 24 h and 48 h of incubation in the presence of FAs are 
interesting (Figure 7A and C) (data 24 h are not shown). The interaction with each 
FA did not change significantly peaks position but caused evident perturbation in 
peak intensity, that continued during the incubation. The plot of normalized inten-
sities as a function of residue number (Figure 7B and D) shows only a uniform 
perturbation of the values, which is characteristic of an interaction which is not 
residue-specific. 
 FA-induced protein secondary structure perturbations monitored by 
circular dichroism 
Circular dichroism (CD) spectroscopy was used to gain insight into changes in sec-
ondary structure of Tau4RD induced by the presence of FA. The far-UV CD spec-
trum of Tau4RD is characteristic of a largely disordered protein, featuring a deep 
minimum centred at 198 nm and the absence of strong negative signals above 205 
nm (Figure 8A). 
Firstly, to evaluate the effects of micelles on the conformation of Tau4RD, the spec-
tra of the protein were collected after the immediate addition of different molar 
excess of FA (P/FA = 1:3, 1:10, 1:25). The CD data (Figures 8B and C) show that 
as the fatty acid concentration increases, the protein spectrum gradually vanishes. 
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This trend is completely different in the presence of another amphipathic micelle, 
formed by SDS. Indeed, the addition of SDS produces a quantitative conversion to 
α-helical structure (Figure 8D), which increases with increasing molar ratio, as re-
ported [5]. These data indicate that in the presence of distinct types of micelles, the 
interaction can perturb the unfolded nature of Tau4RD. 
According to these results, the evolution of the perturbation of the secondary 
structure of Tau4RD was monitored in the presence of FA at different time points, 
choosing as the optimal molar ratio, P/FA 1:3. 
On addition of OLA, the protein spectrum remained unperturbed (Figure 9A), how-
ever, after incubation for 24 h, significant changes were observed. The lineshape 
showed two minima, at 202 and 218 nm, and positive ellipticity was observed be-
low 195 nm. This lineshape can be attributed to a mixture of protein molecules in 
disordered state and in partially ordered conformations, however with no uniquely 
defined secondary structure elements. 
In analogy with OLA, the addition of ARA did not immediately perturb the CD 
spectrum of Tau4RD, but changes were observed after longer incubation (Figure 
9B). The lineshapes observed appeared quite similar to the previous sample and 
exhibited two minima centred at about 200 and 220 nm. 
To better understand the structural perturbations induced by FA, experi-
ments were also performed with heparin, as a further control. The transition of 
Tau4RD from the disordered state to a β-sheet structure after incubation for 24 h 
with heparin was clear from the CD spectrum (Figure 9C), in agreement with pre-
vious studies [6]. 
For comparison purposes, we investigated the interaction of FA with an-
other amyloidogenic protein, α-synuclein (αS). αS can easily form amyloid fibrils 
in vitro without the addition of inducers, and the corresponding CD spectrum was 
consistent with the presence of β-sheet structure (Figure 10A). In the presence of 
ARA, however, the protein turned immediately to α-helical structure and the CD 
spectrum displayed little changes after longer incubation, in agreement with the 
results of Klenerman and co-workers [7] (Figure 10B). Analogous results were ob-
served in αS incubated with OLA (Figure 10C). 
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 Lipid co-aggregates characterization 
Atomic force microscopy (AFM) studies were performed to examine the morphol-
ogy of the co-aggregates formed by interaction with fatty acids. Samples were pre-
pared in the same conditions employed for the above-described NMR and CD 
measurements. Samples were diluted to the optimal concentration and were ad-
sorbed on the surface of the mica for AFM imaging. 
After the immediate addition of the Fatty Acid (OLA or ARA) (Figures 11A and 
B), no significant particles were found adsorbed to the surface of the mica. The 
presence of small particles could be due to homotypic (lipid-only or protein-only) 
assemblies or impurities. After incubation (24 h at 37 °C) samples were diluted and 
adsorbed to the mica again. As evident in the micrography in Figure 11C and D, 
Tau4RD appeared to interact with the bulk of FAs, showing the presence of large 
amorphous aggregates. 
Thus, although very preliminary, the collected results show clearly that the interac-
tion of Tau4RD with FAs determine the formation of larger assemblies which do 
not exhibit the typical fibrillar form of amyloids. 
 Conclusions 
In vitro studies have shown to be particularly useful to investigate the inter-
action effects of fatty acids on Tau4RD aggregates formation. In our work, we 
demonstrate that fatty acids can affect the kinetics and the type of aggregations, as 
well as the structural properties of Tau. Samples characterization shows how Ara-
chidonic Acid and Oleic Acid can induce the formation of Tau adducts, suggesting 
that these phenomena could be correlated firstly to the specific property of FAs to 
form micelles and secondly to their elevated concentration levels in AD. 
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 Figures 
 
Figure 1: Chemical Structures of FAs used in this work and illustration of a Micelle structure. (A) 
Arachidonic Acid (20:4); (B) Oleic Acid (18:1), (C) Fatty acid micelles. 
 
 
Figure 2: Kinetics of protein aggregation followed by ThT-fluorescence. Aggregation assay was 
done at 37 °C for 72 h. Samples contained Tau4RD and FAs at 1:3 molar ratio (A) Tau4RD+Ar-
achidonic Acid; (B) Tau4RD+Oleic Acid. (C) Tau4RD in the presence of Heparin at 4:1 molar 
ratio. 
(A) (B) (C)
0 10 20 30 40 50 60 70 80
0
200
400
600
800
1000
Time (hour)
Fl
uo
re
sc
en
ce
 In
te
ns
ity
 
Tau-Ara
Tau4RD+ARA
Tau4RD
ARA
0 10 20 30 40 50 60 70 80
0
200
400
600
800
1000
Time (hour)
Fl
uo
re
sc
en
ce
 In
te
ns
ity
 
Tau-Ara
Tau4RD+ARA
Tau4RD
ARA
Time (hours Time (hours)
A B
Fl
uo
re
sc
en
ce
 (A
.U
.)
Fl
uo
re
sc
en
ce
 (A
U)
Fl
uo
re
sc
en
ce
 (A
U)
0 10 20 30 40 50 60 70 80
0
1000
2000
3000
4000
Time (h)
Fl
uo
re
sc
en
ce
 In
te
ns
ity
 
Tau4RD+Heparin
Tau4RD
0 10 20 30 40 50 60 70 80
0
200
400
600
800
1000
Ti e (hour)
Fl
uo
re
sc
en
ce
 In
te
ns
ity
 
Tau-Ara
Tau4RD+ARA
Tau4RD
ARA
s)
C
Fl
uo
re
sc
en
ce
 (A
U
)
 93 
  
Figure 3: Non-reducing gradient SDS-PAGE (10-17%) shows the formation of high molecular 
weight co-aggregates, trimers and large oligomers, of Tau4RD in presence of heparin or fatty 
acids after 72 h of incubation. 
 
Figure 4: 1H-NMR profiles of Tau4RD and fatty acids. High-field portion of 1H-NMR spectra 
of 25 μM Tau4RD (blue), 75 μM fatty acid (FA, black), and 25 μM Tau4RD mixed with 75 μM 
fatty acid (red). Measurements were performed at 37 °C. 
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Figure 5: 1H-NMR measurements of Tau4RD monomer depletion and translational diffusion. 
High-field region of 1H-NMR spectra (A) and translational diffusion experiments (B) recorded 
on Tau4RD in the presence of OLA. High-field region of 1H-NMR spectra (C) and translational 
diffusion experiments (D) recorded on Tau4RD in the presence of ARA. In B and D, the intensity 
of a selected signal is shown as a function of the square of the fraction of gradient used. Samples 
contained 25 μM Tau4RD and 75 μM fatty acid. A, C) Spectra were collected on samples that 
were incubated 0 h (gray), 24 h (dark gray), and 48 h (black). B) Samples were incubated 0 h 
(empty circles) and 24 h (filled circles), and asterisks denote data collected on Tau4RD in the 
absence of fatty acid. D) Samples were incubated 0 h (empty squares), 24 h (empty triangles), 48 
h (empty diamonds). B, D) Lines are fitted exponential curves. Aggregation of 100 μM protein 
was induced with 300 μM fatty acid and magnetic stirring. Samples were kept at 37 °C during 
both incubation and measurement. 
 
Figure 6: 1H-15N-NMR spectra of Tau4RD in absence of fatty acid (panel A) and after the imme-
diate addition of Arachidonic Acid (panel B) an Oleic Acid (panel C). 
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Figure 7: Superimposition of two 1H-15N-HSQC NMR spectra of 15N-Tau4RD: (A) after the 
immediate addition of ARA (blue spectrum) and after 48 h of incubation at 37 °C (red spectrum); 
(C) after the immediate addition of OLA (blue spectrum) and after 48 h of incubation at 37 °C 
(red spectrum). Relative signal intensity obtained from HSQC spectra measured on (C) 15N-
Tau4RD: ARA and (D) 15N-TauRD:OLA, after the immediate addition of FA (I0) and after 48h 
(I48h). 
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Figure 8: Effect of micelles on the secondary structure of Tau4RD. Far-UV CD spectra of 
Tau4RD (A) recorded after 0h-24h-72h of incubation at 37°C; (B) in the presence of OLA mi-
celles at different molar ratios (P:FA = 1:3, 1:10, 1:25); (C) in the presence of of ARA micelles 
at a P:FA molar ratio of 1:25 after 0 h, 24 h, 72 h of incubation at 37°C. (D) Effect of SDS micelles 
on Tau4RD at P:SDS molar ratios of 1:125 and 1:100. 
 
Figure 9: CD spectra of Tau4RD in presence of ARA (A) and OLA (B) after incubation at 37 °C. 
Incubation times are indicated in the figures. 
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Figure 10: CD spectra of α-synuclein (A), in presence of Arachidonic Acid (B) and Oleic Acid(C) 
(P/FA 1:3). Incubation times are indicated in the figures. 
 
 
 
A B
C
 98 
Figure 11: AFM micrographs of Tau4RD co-aggregates obtained from the aggregation of Tau4RD in pres-
ence of micelles of fatty acid, immediately after mixing and after 24h of incubation. Oleic Acid micelles at 
t0 (A) and 24h (C), arachidonic acid at t0 (B) and 24h (D). 
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 Supporting Information 
Lipid Micelles 
The chemical structure of lipid molecules is characterized by a hydrophobic 
and hydrophilic region, that determines their behavior in an aqueous environment. 
Hydrophobic regions tend to self-associate, whereas hydrophilic moieties prefera-
bly interact with water and with each other. This leads to the spontaneous formation 
of particular structures such as micelles [8]. 
Micelle represents the simplest association structure, in which the lipid hy-
drophilic head group is in direct contact with the surrounding aqueous phase, 
whereas the hydrophobic region is forming the micelle core (Figure S3). Micelles 
are approximately spherical in shape, although other shapes, are possible, depend-
ing on concentration, temperature, pH and ionic strength. Usually, association in 
micelles occurs when the lipid molecules reach a threshold concentration in solu-
tion known as the Critical Micelle Concentration (CMC) [9]. Below this value, the 
molecules exist as a single chain in a molecular dispersion. However, when mole-
cule concentration is increased, aggregation takes place within a rather narrow con-
centration range. The CMC is therefore defined as the concentration of surfactant 
at a given temperature where the first micelle begins to form [9]. 
Dynamic light scattering (DLS) was used in this work to perform a qualitative anal-
ysis of the CMC value of micelles formed in solution. When the CMC is reached 
in solution, there is a sudden increase in intensity of scattered light due to the for-
mation of micelles (Figure S4). Evidence for micelle formation comes from the 
correlation function curves. Experimental correlation function data for all the con-
centration of DLS measurement are given in Figure S4. The correlation functions 
show very poor signal at very low interception, at very low concentration (below 
the CMC) ≤ 0.01 mM. 
However, when the CMC is reached, the intensity of scattered light increases due 
to the presence of micelles, and the intercepts of correlation function become much 
higher, 0.6-0.9, as seen in the DLS measurement (Figure S4). 
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 Supplementary figures 
 
Figure S1. Translational diffusion of Tau4RD in the presence of fatty acids. The intensity of a 
selected signal is shown as a function of the square of the fraction of gradient used. Samples 
contained 25 μM Tau4RD and no fatty acid (asterisks and fitted curve), 75 μM OLA (empty cir-
cles), or 75 μM ARA (empty squares). Measurements were performed immediately after sample 
preparation, at 37 °C. 
 
Figure S2. Translational diffusion of fatty acid. The displayed NMR diffusion spectra were rec-
orded with 5% (black) and 95% (red) of the maximum gradient strength (53.5 G/cm) and a diffu-
sion delay of 200 ms. The samples contained 75 μM OLA (A) or 500 μM ARA (B). The meas-
urement temperature was 37 °C. 
 
Figure S3: Representation of fatty acid micelle 
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Figure S4: Investigation of micelles formation of fatty acids. Autocorrelation Function (ACF) of 
Arachidonic Acid (A) and Oleic Acid (B) at various concentrations 
 
 
Figure S5: NMR analysis of ARA micelle formation. A) Portion of 1H NMR spectrum of ARA 
dissolved at a concentration of 75 µM (black) or 500 µM (red). The intensity of the spectrum at 
lower concentration was multiplied by 8 for better comparison. B) Diffusion NMR spectra rec-
orded on 75 µM ARA with 5% (black) and 95% (red) of the maximum gradient strength. Peaks 
indicated by green (orange) arrows are attributed to ARA micelles (monomers). 
 
Figure S6: Superimposition of two1H-15N-HSQC NMR spectra of 15N-Tau4RD (blue spectrum) and 
after 48h of incubation at 37 °C (red spectrum), as expected no perturbation are observed.  
  
NMR analysis of ARA micelle formation. A) Portion of 1H NMR spectrum of
ARA dissolved at a concentration of 75 µM (black) or 500 µM (red). The
intensity of the spectrum at lower concentration was multiplied by 8 for
better comparison. B) Diffusion NMR spectra recorded on 75 µM ARA with
5% (black) and 95% (red) of the maximum gradient strength. Peaks indicated
by green (orange) arrows are attributed to ARA micelles (monomers).
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NMR analysis of ARA micelle formation. A) Portion of 1H NMR spectrum of
ARA dissolved at a concentration of 75 µM (black) or 500 µM (red). The
intensity of the spectrum at lower concentration was multiplied by 8 for
better comparison. B) Diffusion NMR spectra recorded on 75 µM ARA with
5% (black) and 95% (red) of the maximum gradient strength. Peaks indicated
by green (orange) arrows are attributed to ARA micelles (monomers).
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4.3 Study of nanoparticle-induced conformational transitions of amyloido-
genic protein Tau at single residue resolution 
Aberrant aggregation of specific proteins and peptides and their progressive 
accumulation as insoluble deposits of amyloid fibrils are hallmarks of a growing 
number of neurodegenerative diseases [1,2]. Among these proteins, Tau, a prototyp-
ical amyloidogenic protein, in solution populates an ensemble of rapidly intercon-
verting structures that eventually transition to higher-order aggregates such as oli-
gomers and fibrils [3]. Perturbing the dynamic interconversion among conforma-
tional states with small molecules, macromolecules, and nanoparticles (NPs) offers 
the possibility to redirect the formation of neurotoxic aggregates [4-7]. 
In recent years, NPs have attracted increasing interest as aggregation mod-
ulators, and have been proposed as systems to either accelerate or inhibit fibrillo-
genesis. The specific effects depend on their properties (size, charge, hydrophobi-
city, material), the environment (pH, ionic strength, temperature), NP/P molar ra-
tios, and the protein intrinsic aggregation propensities [10]. However, despite intense 
investigations, our understanding of how amyloidogenic proteins interact with NPs 
remains limited, and general paradigms are still lacking [12]. 
Solution NMR experiments have been increasingly used to describe the in-
teraction of proteins with NPs at the individual residue level [13]. Indeed, recent ef-
forts demonstrated that several NMR observables, such as chemical shifts, signal 
intensities, amide exchange rates and relaxation parameters, together with newly 
designed saturation transfer experiments, could be successfully employed to char-
acterize the orientation, structure and dynamics of proteins adsorbing onto NP sur-
faces [14-22]. In addition, methodologies have been proposed to investigate protein 
molecules in higher order supramolecular structures [8]. 
In our work, we aimed to explore the general effects of NPs-proteins hybrid as-
semblies, with the goal of contributing to sustained nanotechnology and safe nano-
medicine against amyloid diseases. We selected Ultrasmall Gold Nanoparticles 
(Figure 23), with a core size of about 3 nm, and conjugated with lipoic acid to en-
hance their stabilization, convenient for the investigation of NP-protein supramo-
lecular complexes by NMR spectroscopy. 
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Figure 23: Schematic representation of Lipoic Gold Nanoparticles 
The size is one of the key parameters that can influence NP-biomolecular interac-
tion. Thus, these ultrasmall NPs were selected because may not form a protein co-
rona and possibly lead to a 1:1 protein:NP assembly [9]. Moreover, gold was selected 
as the NPs core material because AuNPs are readily synthesized, easily functional-
ized, and highly stable against oxidative dissolution [10-11]. 
 1H-15N-NMR measurements 
In order to investigate changes in chemical environment of the individual 
amino acid of Tau4RD in presence of NPs, we performed experiments on a high-
resolution NMR spectrometer operating at 1 GHz proton frequency. 
Two-dimensional 1H-15N-HSQC spectra were recorded on Tau4RD in the absence 
(Figure 1A) and in the presence of Lip@AuNPs at different molar ratios (6:1 and 
3:1) (Figure 1B and C).  In these experiments, the protein in the hybrid assemblies 
was in excess with respect to the NPs, therefore both free and bound protein mole-
cules were present in solution. 
The addition of NPs (Figure 1B and C) did not change significantly peaks position 
but caused evident perturbation in peak intensities. Indeed, a progressive decrease 
of protein peaks intensity was observed, due to the formation of larger hybrid as-
semblies where the protein experiences slower rotation tumbling. 
The plots of normalized intensities as a function of residue number (Figure 2) show 
that the interaction is not residue specific but show only a uniform perturbation 
across the residues. 
Lipoic Gold NPs Citrate Gold NPs
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 Transverse Relaxation Measurements 
Further investigation about the possibility to obtain information about the 
NP-bound state of Tau4RD, through the analysis of transverse relaxation rate val-
ues, 15N-R2, was explored. The 15N-R2 values for Tau4RD (Figure 3A) plotted ver-
sus residue number, displayed a fairly homogeneous relaxation profile for the un-
bound state (red dots), as expected for a disordered protein. After addition of NPs, 
the relaxation rates plot (blue dots) displayed only small values, reflecting the fast-
rotational tumbling of all amino acids along the protein sequence, in analogy with 
the sample containing only protein. 
Normally, when NPs are added to the solution containing proteins, the protein 
signals are expected to be perturbed depending on the nature of the NP-protein in-
teraction. On the contrary, in our sample, after the addition of Lip@AuNPs, 15N-R2 
values for all residues did not show increased values indicative of slow rotational 
dynamics (red dots) and all residues exhibited similar behavior as the free state. 
This could be due to a slow exchange regime, in which the bound species dissoci-
ates at a slow rate from the surface of the NPs. In other words, the observed signals 
report on the unbound state and do not appear to be exchange-averaged over the 
bound and unbound forms. 
For comparison purposes, we investigated the transverse relaxation changes 
with another amyloidogenic protein, α-synuclein. As Tau4RD, the 15N-R2 values 
for α-synuclein (Figure 3B) are consistent with the fast mobility of the entire protein 
(blue dots). However, after the addition of NPs, it’s possible to observe a modifica-
tion of the relaxation profile (red dots). The values of the first sixty amino acids 
became much larger compared to the values of α-synuclein alone. Followed, then, 
by a gradual decrease towards the C-terminus region, with values that were essen-
tially identical to those of the free protein. This effect could be due to a lifetime 
line-broadening effect originating from an exchange between free and bound states 
during experiment acquisition.  
 Saturation Transfer Measurements 
In order to obtain information on the interaction kinetics and a residue-by-
residue dynamics, dark-state exchange saturation transfer (DEST) measurements 
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were performed. This innovative solution-NMR method, developed by Fawzi and 
co-workers, relies on saturation transfer to provide information on the invisible state 
(“dark”) (nanoparticles-protein) in chemical exchange with visible states (protein). 
In other words, in this kind of experiment, when the invisible state is saturated [8,12], 
the saturation will be transferred by the chemical exchange to the visible state, lead-
ing to a decrease in the intensity of the latter [13]. Combining DEST and two-dimen-
sional 1H-15H-HSQC experiments allows for a single residue resolution of dynamic 
information of the relaxation. Furthermore, combining the measurement of the re-
laxation rate in the presence and absence of nanoparticles (ΔR2), it is possible char-
acterize the interaction kinetic and molecular motion of bound states. 
The experimental 15N-DEST profiles and ΔR2 data, collected from the sample 
Tau4RD:Lip@AuNP, molar ratio 6:1, as described in Materials and Method (3.8.5) 
were plotted using DESTfit software [12] (Figure 5A) . 
The obtained saturation profiles clearly display the absence of an optimal match 
between the experimental best-fit parameters obtained with DESTfit (Figure 5).  
This result could be explained by the direct observation of the ΔR2. The values of 
ΔR2 (Figure 4A) were equal to zero at all residue positions, thus a ΔR2 not greater 
than 0.2 s-1 is directly connected with an insufficient population of dark state, or a 
timescale not appropriate for observing the effect. Consequently, as next step, it 
will necessary to modify sample conditions on order to promote an increased con-
version rate from the NMR-visible to the dark species. This can often be accom-
plished by increasing the concentration of the dark state. However, the absence of 
saturation could also due to saturation power too weak. Thus, it will be necessary 
also to increase the saturation power, in the next experiment. 
On the contrary, for the sample α-syn:Lip@AuNPs, the large difference of 
ΔR2 values between the bound and the free state, enable the observation of DEST 
(Figure 4B and 5B). The observed residue-specific saturation transfer profile can 
be attributed to a lifetime line-broadening effect originating from an exchange be-
tween free and bound states during experiment acquisition. 
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 Conclusion 
The interaction between Ultrasmall Gold Nanoparticles and Tau4RD has 
been highlighted notably by NMR spectroscopy. The presence of nanoparticles pro-
duced a variation of the protein fingerprint observed with 1H-15N-HSQC spectra. 
Indeed, the 2D NMR data indicated a general decrease in signals intensity, due to 
the formation of the hybrid assemblies (Figure 1 and 2). At present, we were not 
able to gather information on the bound state based on relaxation measurements 
and DEST spectroscopy, possibly due unfavorable kinetics of exchange (Figure 5). 
Thus, further investigations are needed to fully characterize the inter-struc-
ture between these two species. In order to later characterized the implication of 
this interaction in the protein aggregation processes. 
 Figures 
 
Figure 1: HSQC of Tau4RD in absence/presence of Lip@AuNPs. (A) Tau4RD;                                    
(B) Tau4RD:Lip@AuNPs (6:1); (C) Tau4RD:Lip@AuNPs (3:1). Spectra were collected on 1 
GHz NMR spectrometer equipped with solution-state cryogen probe. Experiment temperature: 
283 K. (Upon addition of NPs, almost negligible chemical shift variations are observed). 
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Figure 2: Relative signal intensities obtained from 15N-HSQC spectra measured on 15N-
Tau4RD in 10mM KPi pH 6.8 at 283 K, in presence of Lip@AuNPs at different molar ration 
6:1 in blue and 3:1 in red. 
 
Figure 3: 15N transverse relaxation rate value. (A) Plot of 15N-R2 values of Tau4RD measured 
in the absence (blue dots) and presence of Lip@AuNPs, for a molar ratio of 6:1 (red dots) (green 
regions represent the two hexapeptide motifs). (B) Plot of R2 value of α-Synuclein measure in 
the absence (blue dots) and presence of Lip@AuNPs, for a molar ratio of ~ 20:1 (red dots). 
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Figure 4: ΔR2 value. Difference of R2 values (showed in figure 3A and B) measured on samples of (A) 
Tau4RD and (B) α-synuclein, in the absence and presence of NPs. (green regions represent the two 
hexapeptide motifs). 
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Figure 5: 15N-DEST profiles observed for some representative residue for Tau4RD (A) and α-synuclein (B) 
in presence of Lip@AuNPs. Screenshots of figure output from the DESTfit software: comparison of experi-
mental (red dots) and calculated (blue lines) data. 
  
B
 111 
 References 
 [1] Ross, C. A.; Poirier, M. A. Protein Aggregation and Neurodegenerative Disease. Nat. Med. 
2004, 10 Suppl, S10-17. https://doi.org/10.1038/nm1066. 
 [2] Soto, C.; Pritzkow, S. Protein Misfolding, Aggregation, and Conformational Strains in 
Neurodegenerative Diseases. Nat Neurosci 2018, 21 (10), 1332–1340. 
https://doi.org/10.1038/s41593-018-0235-9. 
 [3] Nath, A.; Sammalkorpi, M.; DeWitt, D. C.; Trexler, A. J.; Elbaum-Garfinkle, S.; O’Hern, 
C. S.; Rhoades, E. The Conformational Ensembles of α-Synuclein and Tau: Combining 
Single-Molecule FRET and Simulations. Biophysical Journal 2012, 103 (9), 1940–1949. 
https://doi.org/10.1016/j.bpj.2012.09.032. 
 [4] Álvarez, Y. D.; Fauerbach, J. A.; Pellegrotti, J. V.; Jovin, T. M.; Jares-Erijman, E. A.; 
Stefani, F. D. Influence of Gold Nanoparticles on the Kinetics of α-Synuclein Aggregation. 
Nano Lett. 2013, 13 (12), 6156–6163. https://doi.org/10.1021/nl403490e. 
 [5] Eisele, Y. S.; Monteiro, C.; Fearns, C.; Encalada, S. E.; Wiseman, R. L.; Powers, E. T.; 
Kelly, J. W. Targeting Protein Aggregation for the Treatment of Degenerative Diseases. 
Nat Rev Drug Discov 2015, 14 (11), 759–780. https://doi.org/10.1038/nrd4593. 
 [6] Kurnik, M.; Sahin, C.; Andersen, C. B.; Lorenzen, N.; Giehm, L.; Mohammad-Beigi, H.; 
Jessen, C. M.; Pedersen, J. S.; Christiansen, G.; Petersen, S. V.; et al. Potent α-Synuclein 
Aggregation Inhibitors, Identified by High-Throughput Screening, Mainly Target the Mon-
omeric State. Cell Chemical Biology 2018, 25 (11), 1389-1402.e9. 
https://doi.org/10.1016/j.chembiol.2018.08.005. 
 [7] Pujols, J.; Peña-Díaz, S.; Lázaro, D. F.; Peccati, F.; Pinheiro, F.; González, D.; Carija, A.; 
Navarro, S.; Conde-Giménez, M.; García, J.; et al. Small Molecule Inhibits α-Synuclein 
Aggregation, Disrupts Amyloid Fibrils, and Prevents Degeneration of Dopaminergic Neu-
rons. PNAS 2018, 115 (41), 10481–10486. https://doi.org/10.1073/pnas.1804198115. 
 [8] Fawzi, N. L.; Ying, J.; Ghirlando, R.; Torchia, D. A.; Clore, G. M. Atomic-Resolution 
Dynamics on the Surface of Amyloid-β Protofibrils Probed by Solution NMR. Nature 
2011, 480 (7376), 268–272. https://doi.org/10.1038/nature10577. 
 [9] Lira, A. L.; Ferreira, R. S.; Torquato, R. J. S.; Zhao, H.; Oliva, M. L. V.; Hassan, S. A.; 
Schuck, P.; Sousa, A. A. Binding Kinetics of Ultrasmall Gold Nanoparticles with Proteins. 
Nanoscale 2018, 10 (7), 3235–3244. https://doi.org/10.1039/C7NR06810G. 
 [10] Daniel, M.-C.; Astruc, D. Gold Nanoparticles: Assembly, Supramolecular Chem-
istry, Quantum-Size-Related Properties, and Applications toward Biology, Catalysis, and 
Nanotechnology. Chem. Rev. 2004, 104 (1), 293–346. https://doi.org/10.1021/cr030698+. 
 [11] De Roe, C.; Courtoy, P. J.; Baudhuin, P. A Model of Protein-Colloidal Gold In-
teractions. J. Histochem. Cytochem. 1987, 35 (11), 1191–1198. 
https://doi.org/10.1177/35.11.3655323. 
 112 
 [12] Fawzi, N. L.; Ying, J.; Torchia, D. A.; Clore, G. M. Probing Exchange Kinetics 
and Atomic Resolution Dynamics in High-Molecular-Weight Complexes Using Dark-State 
Exchange Saturation Transfer NMR Spectroscopy. Nat Protoc 2012, 7 (8), 1523–1533. 
https://doi.org/10.1038/nprot.2012.077. 
 [13] Giuntini, S.; Cerofolini, L.; Ravera, E.; Fragai, M.; Luchinat, C. Atomic Structural 
Details of a Protein Grafted onto Gold Nanoparticles. Sci Rep 2017, 7 (1), 1–6. 
https://doi.org/10.1038/s41598-017-18109-z. 
 [14] Haiss, W.; Thanh, N. T. K.; Aveyard, J.; Fernig, D. G. Determination of Size and 
Concentration of Gold Nanoparticles from UV−Vis Spectra. Anal. Chem. 2007, 79 (11), 
4215–4221. https://doi.org/10.1021/ac0702084 
  
 113 
 Supporting Information 
Gold Nanoparticle Preparation 
Ultrasmall Lipoic Gold Nanoparticles were concentrated by several centrifugation 
from 0.6 µM (stock) to enough concentration that allowing their utilization for 
NMR measurement, and finally washed in the final buffer (10mM KPi pH 6.8). The 
concentration was calculated according the method developed by Haiss et al. [14]. 
Depending on the stock solution, the concentration obtained varies from 10 to 12 
µM. UV-vis measurements were performed on a Nanodrop 2000C spectrophotom-
eter (Thermo Scientific) at room temperature. In order satisfy the Beer-Lambert law 
condition, each stock was diluted by a dilution factor from 20 to 40. A spectral 
width from 300 to 800 nm was used in each case (Figure S1). 
The measured absorbance at A450 nm was then divided by the extinction coefficient 
(ε450nm) determined from the tables of the publication of Haiss at al. [14]. 
 
Figure 1: UV-vis absorption spectrum of Lip@AuNPs. The spectrum shows the absorbance of 
1:20 diluted NPs solution. 
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